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Abstract  
Despite the restricted permeability of the blood-brain barrier (BBB), the brain is 
a privileged organ regarding the appearance of metastases, particularly from breast 
cancer. Patients with brain metastases from breast cancer have a severe prognosis, 
rendering this issue a serious oncologic problem that deserves further attention. 
Therefore, additional studies are required to establish when breast cancer cells cross the 
brain endothelium and what are the routes used for the transendothelial migration, to 
understand what is their precise phenotype along the processes of transmigration and 
establishment of brain metastases, to determine the alterations occurring in brain 
endothelium, to study how endothelial cells communicate with malignant ones to promote 
the attraction of malignant cells into the brain vasculature and tumour-associated vascular 
development. Based on this, we aimed at establishing the temporal profile of breast cancer 
metastasization to the brain and characterize the metastasizing cells phenotype, as well 
as, to investigate the vascular events and BBB properties along the process of 
metastasization to this target organ. In addition, we aimed to assess signalling 
mechanisms involved in attraction of carcinoma cells into the brain and proliferation in 
the nervous tissue. To establish the temporal evolution of the players involved in such 
processes, we used cerebella, cranial hippocampi, and striata of female mice inoculated 
with 4T1 breast cancer cells sacrificed at 5 hours, 3 days, 7 days or 10 days, and of female 
mice injected with vehicle (control) sacrificed at 5 hours. Our results showed the presence 
of brain metastasis of breast cancer at 7-days after inoculation, which increased thereafter. 
The malignant cells crossed the BBB as mesenchymal cells and, once inside the brain, 
these cells underwent a complete or partial mesenchymal-epithelial transition to acquire 
the epithelial characteristics that allow the establishment of new tumours. In addition, the 
process of brain metastasization of BC contributed to the downregulation of the tight 
junction protein claudin-5 of brain microvascular endothelial cells, as well as to the 
entrance of the blood-borne component thrombin in brain parenchyma. On the other hand, 
hypervascularization in cranial hippocampus appeared to be associated to the process of 
brain colonization by breast cancer cells. Regarding the role of platelet-derived growth 
factor B signalling along the process of brain metastasization, we found that this growth 
factor was expressed by tumour cells and its expression increased during the formation 
of brain metastasis. Interestingly, a continuous entrance of cysteine-X amino acid-
cysteine receptor 4 (CXCR4)-positive cells into the brain parenchyma appeared to occur 
 
 
along the process of brain metastasization of breast cancer. In sum, this study contributes 
to clarify the time-course and interdependence of the signalling events, BBB breach and 
phenotypic transition of malignant cells along endothelial transposition and brain 
metastases establishment by breast cancer cells. Moreover, the demonstration of early 
cellular and molecular events points to novel targets for modulation in order to prevent 
metastasis formation and development.   
 
Keywords: Blood-brain barrier; brain metastasis; breast cancer; phenotypic transition; 
transendothelial migration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
Apesar da barreira hematoencefálica (BHE) ter uma permeabilidade restrita, o 
cérebro é um órgão preferencialmente afetado pelo aparecimento de metástases, 
particularmente de cancro mama. Pacientes com metástases cerebrais provenientes do 
cancro da mama têm um prognóstico severo, tornando a metastização num sério problema 
oncológico que merece toda a atenção. Por este motivo, novos estudos são necessários 
para estabelecer quando é que as células cancerígenas da mama atravessam o endotélio 
cerebral e quais são as vias que utilizam para migrarem através do endotélio, para se 
perceber qual o fenótipo que têm ao longo dos processos de migração para dentro do 
encéfalo e durante o estabelecimento de metástases, para determinar as alterações que 
ocorrem no endotélio cerebral, para estudar como as células endoteliais comunicam com 
as células malignas para promover a atracão das células cancerígenas da mama para a 
vasculatura do encéfalo e o desenvolvimento vascular associado ao tumor. Com base 
nisto, tivemos com objetivos estabelecer o perfil temporal da metastização do cancro da 
mama para o encéfalo e caracterizar o fenótipo destas mesmas células, assim como, 
estudar as alterações vasculares e as propriedades da BHE ao longo do processo de 
metastização para este órgão secundário. Para além disso, também pretendíamos avaliar 
os mecanismos de sinalização envolvidos na atracão das células tumorais para o encéfalo 
e na proliferação no tecido nervoso. Para estabelecer a evolução temporal dos 
intervenientes envolvidos em tais processos, utilizámos cerebelos, hipocampos craniais e 
estriados de ratinhos fêmea inoculados com células cancerígenas da mama 4T1 
sacrificados às 5 horas, 3 dias, 7 dias, ou 10 dias, e de ratinhos fêmea injetados com 
veículo (controlo) sacrificados às 5 horas. Os nossos resultados mostraram a presença de 
metástases cerebrais do cancro mama 7 dias após a inoculação, aumentando ao longo do 
tempo. As células malignas atravessaram a BHE como células mesenquimais e, uma vez 
dentro do encéfalo, estas células sofreram uma transição completa ou parcial de fenótipo 
mesenquimal para epitelial para adquirirem as características epiteliais necessárias para 
o estabelecimento de novos tumores no encéfalo. Além disso, o processo de metastização 
cerebral do cancro da mama contribuiu para a diminuição da expressão da proteína das 
junções de oclusão claudina-5 nas células endoteliais microvasculares cerebrais, assim 
como para a entrada do componente sanguíneo trombina no parênquima cerebral. Por 
outro lado, o aumento de vascularização no hipocampo cranial aparentou estar associado 
ao processo de colonização do encéfalo pelas células cancerígenas da mama. 
 
 
Relativamente ao papel da sinalização do fator de crescimento B derivado de plaquetas 
ao longo do processo de metastização cerebral, descobrimos que as células tumorais 
expressavam este fator de crescimento e que a sua expressão aumentou durante a 
formação de metástases no encéfalo. Curiosamente, a entrada contínua de células que 
expressam o recetor CXCR4 para dentro do parênquima cerebral aparentou ocorrer ao 
longo do processo de metastização cerebral do cancro da mama. Deste modo, este estudo 
contribui para clarificar o curso temporal e a interdependência de vias de sinalização, a 
quebra da BHE e a transição fenotípica das células malignas ao longo na transposição do 
endotélio e estabelecimento de metástases cerebrais pelas células cancerígenas da mama. 
Além disso, a demonstração dos eventos celulares e moleculares iniciais aponta para 
novos alvos para modulação de modo a prevenir a formação e desenvolvimento de 
metástases.   
 
Palavras-chave: Barreira hematoencefálica; cancro da mama; metástase cerebral; 
migração transendotelial; transição fenotípica.  
 
 
 
 
  
 
 
Acknowledgements/Agradecimentos 
Gostaria primeiramente de agradecer à Professora Alexandra Brito, orientadora 
deste trabalho. Sem a sua persistência, este projeto nem teria ganho pernas para andar. 
Não posso deixar de mencionar todo o seu espírito crítico e a sua exigência que me fez 
sempre tentar dar o meu melhor. Obrigada por toda a ajuda e orientação a delinear o passo 
seguinte.  
Agradeço à Professora Mafalda Videira por todo o suporte e ajuda que deu ao 
longo deste ano e por me ter integrado tão bem no seu grupo de investigação. 
To the Hungarian research group that collaborate with us, especially to Doctors 
Imola Wilhelm and István A. Krizbai, I would like to thank you for the opportunity to 
work with you. I hope that this collaboration continues to yield results. 
Agradeço ao Professor Rui Malhó da Faculdade de Ciência pela disponibilidade, 
pelo apoio e pela flexibilidade demonstrados ao longo do ano. Sem as idas ao 
microscópio, este estudo não seria nada. Gostaria também de agradecer ao físico Telmo 
Nunes por toda a paciência e compreensão, principalmente na reta final deste projeto. 
Margarida e Sara, o que teria sido de mim sem vocês? Margarida, a ti agradeço 
pela amizade genuína, por todo o bom ambiente que proporcionaste e por todos os 
momentos em que precisava daquele abraço e tu estavas lá para mo dar. Obrigada do 
fundo do meu coração. Sara, a ti agradeço por todas as “baboseiras” que dizes e por toda 
a tua “boa” música e os teus(/do Luís) vídeos que animavam qualquer dia. Obrigada por 
seres a amiga incrível que és! 
Alicia, obrigada por seres um ser fora do comum, tu és a pessoa que mais me 
inspira a fazer mais e melhor. Inês, apesar da distância, estiveste/estarás sempre por perto. 
Mel, a ti agradeço por seres a pessoa especial que és. Nuno, obrigada pela tua 
espontaneidade e iniciativa para me vires chatear de vez em quando. Tides, a ti agradeço 
pela amizade inalterável e incondicional que te “obrigou” a ouvir-me tantas e tantas vezes. 
E Vinte, obrigada por todos os sermões, por todas as tentativas para largar o computador 
e sair de casa. Gosto imenso de cada um vocês! 
Pessoal de casa, obrigada por tudo. Em especial, Alina agradeço-te por toda a tua 
curiosidade e por todo o teu interesse em saber mais e mais; ao Daniel e ao Nuno por 
todas as noites que me obrigaram a ir para sala, por todas as noitadas na cozinha, por 
todas as horas de sono perdidas à vossa pala e por se preocuparem comigo. Vocês são os 
maiores! 
 
 
Pessoal do Núcleo, obrigada por terem deixado que aqui a velhota ainda pudesse 
participar na organização dos eventos deste ano. Sem vocês, acreditem que teria batido 
muitas mais vezes com a cabeça na parede. Ter trabalho convosco, especialmente 
integrada na equipa da Publicidade, foi incrível e foi muito bom ver que o espírito de 
equipa continua bem vivo neste Núcleo.  
Aos meus amigos de longa data, Inês, Tiago e Zé, agradeço-vos pela amizade que 
continua a perdurar. Como a Inês e eu costumamos dizer, agora que já nos aturamos há 
mais de oito anos, já não temos volta a dar! 
Por último, mas nunca menos importante, agradeço por tudo à minha família e, 
em especial, a ti mãe. Tu que foste incondicional ao longo deste ano, estiveste sempre lá 
para me ouvir, desde as histórias mais hilariantes até às lamúrias e às queixas. Obrigada 
por todos os esforços que fizeste e continuas a fazer por mim. Se não fosses tu, esta futura 
cientista (espero) nem teria saído do Algarve. Adoro-te, mãe! E desculpa as longas 
semanas de ausências, mas quero que saibas que não há um dia em que não pense em ti, 
no pai e no “godinho” e que não sinta saudades vossas. 
 
 
 
 
i 
 
Index 
 
Figure Index ................................................................................................................ iii 
Table Index ................................................................................................................. iv 
Abbreviations ............................................................................................................... v 
Chapter I ......................................................................................................................... 1 
Abstract ........................................................................................................................ 3 
Resumo ........................................................................................................................ 4 
1. Breast cancer ............................................................................................................ 5 
2. From primary tumour to secondary organ ............................................................... 9 
2.1. Epithelial-mesenchymal transition ........................................................... 12 
2.2. Local invasion .......................................................................................... 15 
2.3. Intravasation ............................................................................................. 18 
2.4. Survival in circulation .............................................................................. 22 
3. Brain metastasization ............................................................................................. 24 
3.1. Extravasation and role of the blood-brain barrier ..................................... 25 
3.2. Proliferation in brain microenvironment .................................................. 31 
3.3. Mesenchymal-epithelial transition and brain colonization ....................... 36 
4. Conclusion ............................................................................................................. 39 
5. Aims ....................................................................................................................... 40 
6. References .............................................................................................................. 41 
Chapter II ...................................................................................................................... 57 
Abstract ...................................................................................................................... 59 
Resumo ...................................................................................................................... 60 
1. Introduction ............................................................................................................ 61 
2. Materials and methods ........................................................................................... 63 
2.1. Cell culture and animals ........................................................................... 63 
2.2. Histology .................................................................................................. 63 
2.3. Reagents and antibodies ........................................................................... 64 
2.4. Haematoxylin and eosin staining .............................................................. 65 
2.5. Immunofluorescence and immunohistochemistry .................................... 65 
2.6. Data analysis ............................................................................................. 67 
2.7. Statistical analysis .................................................................................... 68 
3. Results .................................................................................................................... 69 
3.1. Brain metastases occur from 7-days onwards after inoculation ............... 69 
3.2. Malignant cells undergo a mesenchymal-epithelial transition ................. 69 
ii 
 
3.3. Metastasization involves a disruption of the BBB by the paracellular 
pathway ………………………………………………………………………………...76 
3.4. Formation of brain metastasis requires increased vascularization ........... 81 
3.5. Malignant cells express PDGF-B ............................................................. 81 
3.6. Malignant cells express CXCR4............................................................... 83 
4. Discussion .............................................................................................................. 85 
Acknowledgements .................................................................................................... 91 
5. References .............................................................................................................. 91 
Chapter III .................................................................................................................... 95 
Concluding remarks and perspectives ....................................................................... 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Figure Index 
 
Chapter I 
Introduction 
Figure 1 Schematic representation of the mammary duct and of the alterations 
occurring during the progression of breast cancer (BC) ….…………………………….10 
Figure 2 Schematic representation of epithelial-mesenchymal transition (EMT), a 
process by which epithelial breast cancer cells acquire mesenchymal characteristics ....13 
Figure 3 Schematic representation of the transendothelial migration (TEM) 
pathways during the intravasation process …….……….………………...…...….…….20 
Figure 4 Schematic representation of key steps of extravasation of a breast cancer 
cell (BCC) …...………….…………...…………………...………………….……...….27 
Figure 5 Schematic representation of key interactions between breast cancer cell 
(BCC) and neuron, astrocyte, microglia, and pericyte in brain microenvironment ….…34 
 
 
Chapter II 
Results 
Figure 1 Tumour area occupied by breast cancer cells along the process of brain 
metastasization ……………………………………………………………………...….70 
Figure 2 Changes in the expression of the mesenchymal marker N-cadherin by 
breast cancer cells along the process of brain metastasization ……………………....….71 
Figure 3 Entrance of vimentin-positive breast cancer cells and establishment of 
tomato lectin-positive macrometastases along the process of brain metastasization .......72 
Figure 4 Phenotypic changes associated to mesenchymal-epithelial transition of 
breast cancer cells along the process of brain metastasization ………....……………….74 
Figure 5 Changes in the expression of the mesenchymal marker vimentin and the 
epithelial marker pan Cytokeratin by breast cancer cells associated to  
mesenchymal-epithelial transition along the process of brain metastasization .….….….75 
Figure 6 Endothelial tight junction protein claudin-5 changes along the process of 
brain metastasization of breast cancer ...………………….….……………...………….77 
Figure 7 Entrance of the blood-borne component thrombin into the brain 
parenchyma along the process of brain metastasization of breast cancer ....…………….79 
iv 
 
Figure 8 Microvascular density changes along the process of brain metastasization 
of breast cancer ...…………………………………….…….…………………………...80 
Figure 9 Changes in the expression of the platelet-derived growth factor B  
(PDGF-B) by breast cancer cells along the process of brain metastasization …..……….82 
Figure 10 Changes in the expression of cysteine-X amino acid-cysteine receptor 
4 (CXCR4) by breast cancer cells along the process of brain metastasization ………….84 
 
 
 
Table Index 
 
Chapter I 
Introduction 
Table 1 Tumour, node, and metastasis (TNM) staging according to the American 
Joint Committee on Cancer (AJCC) staging system …………………………….……….6 
 
Chapter II 
Materials and methods 
Table 1 Percent distribution of metastases in each brain region of mice injected 
with 4T1 cells along time ………………………………………...………………….….64 
Table 2 Summary of the antibodies and experimental conditions used for 
immunofluorescence and immunohistochemical analysis ....……………...........……...66 
 
 
 
 
 
 
 
 
 
v 
 
Abbreviations 
12(S)-HETE 12(S)-hydroxyeicosatetraenoic acid 
ADAM A disintegrin and metalloproteinase 
AJ Adherens junction 
AJCC American Joint Committee on Cancer 
BBB Blood-brain barrier 
BC Breast cancer 
BCC Breast cancer cell 
BHE Barreira hematoencefálica 
BM Basement membrane 
BMVEC Brain microvascular endothelial cell 
BSA Bovine serum albumin 
bTNM Biologic tumour, node, and metastasis 
CA California 
CD Cluster of differentiation 
CK Cytokeratin 
CNS Central nervous system 
CTC Circulating tumour cell 
Cx Connexin 
CXCL12 Cysteine-X amino acid-cysteine ligand 12 
CXCR4 Cysteine-X amino acid-cysteine receptor 4 
DAB 3,3’-diaminobenzidine tetrahydrochloride 
DAPI 4’,6-diamidino-2-phenylindole 
EC Endothelial cell 
E-cadherin Epithelial cadherin 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EMT Epithelial-mesenchymal transition 
EndMT Endothelial-mesenchymal transition 
ER Oestrogen receptor 
E-selectin Endothelial selectin 
FCT Fundação para a Ciência e Tecnologia 
GABA γ-aminobutyric acid 
GJ Gap junction 
H&E Haematoxylin and eosin 
HER2 Human epidermal growth factor receptor 2 
HGFR Hepatocyte growth factor receptor 
HGF/SF Hepatocyte growth factor/scatter factor 
HRP Horseradish peroxidase 
ICAM-1 Intercellular adhesion molecule-1 
vi 
 
 IF Immunofluorescence 
IHC Immunohistochemistry 
JAM Junctional adhesion molecule 
Lhx2 LIM homeobox gene 2 
MA Massachusetts 
Mc Monoclonal 
MET Mesenchymal-epithelial transition 
MLC Myosin light chain 
MLCK Myosin light chain kinase 
MMP Matrix metalloproteinase 
MO Missouri 
MUC1 Mucin 1 
MW Microwave 
NA Not applicable 
N-cadherin Neuronal cadherin 
NKFIH National Research, Development and Innovation 
PBS Phosphate-buffered saline 
Pc Polyclonal 
PDGF Platelet-derived growth factor 
PDGFR-β Platelet-derived growth factor receptor beta 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
PR Progesterone receptor 
PSGL-1 Platelet selectin glycoprotein ligand-1 
OTKA Hungarian Scientific Research Fund 
ROS Reactive oxygen species 
SEM Standard error of mean 
sLex Sialyl Lewis x 
Snail Zinc finger protein snail 1 
TEM Transendothelial migration 
TGF-β Transforming growth factor beta 
TJ Tight junction 
TNM Tumour, node, and metastasis 
TX Texas 
UK United Kingdom 
USA United States of America 
VCAM-1 Vascular cell adhesion molecule-1 
VE Vascular endothelial 
VEGF Vascular endothelial growth factor 
ZEB Zinc finger E-box-binding homeobox 
ZO Zonula occludens 
  
 
 
  
  
 
Chapter I 
1 
 
 
 
 
 
 
 
Chapter I 
 
Brain metastasization of breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain metastasization of breast cancer 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work presented in this chapter corresponds to the following manuscript submitted 
for publication: 
Brain metastasization of breast cancer 
Custódio-Santos T, Videira M, Brito MA 
Chapter I 
3 
 
Abstract  
Breast cancer can lead to formation of metastases in distant organs, such as the 
brain, which is commonly associated with diminished quality of life. In addition, central 
nervous system metastases have been reported in 12-31% of breast cancer patients, and 
the incidence is increasing with the improvement of primary tumours treatment by 
therapeutic agents that do not cross the blood-brain barrier, thus rendering the brain a 
vulnerable organ. Moreover, the survival of patients with breast cancer metastatic to the 
central nervous system is generally poor, with reports of a 1-year survival rate of 20%. 
Therefore, a better knowledge of the determinants of brain metastasization is essential for 
the identification of patients at risk of brain metastases formation, and for the 
development of novel preventive therapeutic strategies. Here, we summarize and discuss 
the current data about the multistep process of brain metastasization, ranging from the 
output of cancer cells from the primary tumour to their colonization in the brain, which 
involves the epithelial-mesenchymal transition that facilitates the invasion of mammary 
tissue, the intravasation into circulation, the survival through the vasculature that allows 
the arrest of the most metastatic cancer cells at brain microvasculature, and the 
extravasation towards this secondary organ. The several phases of extravasation are also 
dissected, namely the rolling, adhesion, and transendothelial migration across brain 
microvascular endothelial cells, and the transcellular passage pathways are addressed. 
Furthermore, the proliferation of metastatic cancer cells, and their colonization in the 
brain, the change in malignant cells phenotype via mesenchymal-epithelial transition, and 
the importance of the microenvironment in the formation of brain metastases are 
inspected. Finally, the role of angiogenesis along the process of brain metastasization is 
also address, playing a crucial role not only in primary tumour growth, but also in spread 
and proliferation of cancer cells. Such detailed cellular and molecular characterization of 
brain metastasization process contributes to an in-depth understanding of the malignant 
behaviour. 
 
Keywords: Brain metastasis; breast cancer; epithelial-mesenchymal transition; 
transendothelial migration; tumour microenvironment. 
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Resumo  
O cancro da mama pode levar à formação de metástases em órgãos distantes, como 
por exemplo o cérebro, e esta formação de tumores secundários está normalmente 
associada à diminuição da qualidade de vida dos pacientes. Para além disso, metástases 
no sistema nervoso central têm sido reportadas em 12-31% dos pacientes e a incidência 
está a aumentar com o melhoramento do tratamento dos tumores primários através de 
agentes terapêuticos que não atravessam a barreira hematoencefálica, tornando assim o 
cérebro um órgão vulnerável à formação de tumores secundários. A taxa de sobrevivência 
de pacientes com cancro da mama metastático para o sistema nervoso central é geralmente 
reduzida, com estudos a reportarem uma taxa de sobrevivência de um ano de 20%. 
Portanto, um melhor conhecimento dos intervenientes envolvidos na metastização 
cerebral é essencial para a identificação de pacientes em riscos de desenvolverem 
metástases cerebrais e para o desenvolvimento de novas estratégias terapêuticas 
preventivas. Deste modo, nós sumariamos e discutimos a informação atual acerca do 
processo de metastização do cérebro que compreende um conjunto de passos desde a 
saída das células cancerígenas do tumor primário até à sua colonização no cérebro, 
envolvendo a transição epitelial-mesenquimal que facilita a invasão do tecido mamário, 
a entrada no sistema circulatório, a sobrevivência através da vasculatura que permite a 
chegada das células cancerígenas com maior potencial metastático à micro-vasculatura 
do cérebro, e a extravasação para dentro deste órgão secundário. As três fases da 
extravasação também são examinadas, nomeadamente o rolamento, a adesão e a migração 
por entre as células endoteliais micro-vasculares do cérebro, e as vias da migração  
trans-celular são abordadas. Para além disso, a proliferação das células cancerígenas 
metastáticas e a sua colonização no cérebro, a mudança de fenótipo por parte das células 
malignas através da transição mesenquimal-epitelial e a importância do micro-ambiente 
na formação de metástases cerebrais são discutidas. Por fim, o papel da angiogénese ao 
longo do processo de metastização do cérebro também é abordado, tendo este processo 
um papel crucial não só no crescimento do tumor primário, como também na 
disseminação e proliferação das células cancerígenas. Assim, a caracterização celular e 
molecular detalhada do processo de metastização cerebral contribui para uma 
compreensão cada vez mais aprofundada do comportamento de uma célula maligna. 
 
Palavras-chave: Cancro da mama; metástase cerebral; microambiente tumoral; migração 
transendotelial; transição epitelial-mesenquimal.  
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1. Breast cancer 
Breast cancer (BC) is a malignant tumour that usually starts in the epithelial cells 
of the mammary ducts, which are structures responsible for drainage of milk from the 
lobules secretory acini to the nipple during lactation (Videira et al. 2014). It is considered 
the most frequently diagnosed cancer in women, with estimated 1.7 million new cases 
worldwide and nearly 521,900 related deaths in 2012 (Torre et al. 2015). The early 
detection of this cancer through a mammography screening increases the chances for 
successful treatment and consequently decreases the mortality from BC (Heinävaara et 
al. 2016). For early-stage BC, the typical treatment procedure involves either mastectomy 
(total removal of the breast) or lumpectomy (removal of breast tumour and some of the 
normal surrounding tissue followed by radiation therapy) plus adjuvant treatment 
(Zujewski 2016). Early surgical intervention has made an impact in preventing the 
recurrence of BC. However, this solid cancer is not always timely diagnosed, and in more 
aggressive and advanced stages the recurrence at distant organs of the body is 
overwhelming. 
All cancers are classified at diagnosis due to its importance for prognosis and 
responsiveness to therapy. The most widely used BC classification is the tumour, node, 
and metastasis (TNM) staging system that is based on tumour size (T), regional nodal 
involvement (N), and distant metastasis (M), and divides BC in four stages (Whitman et 
al. 2006), as summarized in Table 1. Another classification considers non-anatomical 
factors such as biomarkers, and distributes BC patients according to the expression of 
receptors in three groups: hormone receptor-positive when patient presents either 
oestrogen receptor (ER) or progesterone receptor (PR); human epidermal growth factor 
receptor 2 (HER2)-positive when HER2 is overexpressed; and triple-negative when the 
patient is hormone receptors-negative and HER2-negative (Mouttet et al. 2016). The 
hormone receptors and HER2 are cell surface receptors present in normal breast cell, and 
their cross-talk results in a positive feedback to cell cycle, survival, and proliferation 
(Chung et al. 2002, Caldon 2014). However, in BC cells (BCCs), the overexpression of 
HER2 together with DNA damage induced by high levels of oestrogen lead to deregulated 
proliferation and growth of these cells, contributing to the initiation and progression of 
BC. Among the three groups, the triple-negative phenotype is associated with worse 
survival as compared with patients with the expression of the receptors (Ovcaricek et al. 
2011). So, understanding of each group of patients at a molecular level allows not only 
de  
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Table 1 Tumour, node, and metastasis (TNM) staging according to the American Joint 
Committee on Cancer (AJCC) staging system. 
 
deciding the most effective treatment for each patient, but also to study and develop more 
specific therapeutic drugs. Since these two classification systems are routinely used in 
clinical practice, Bagaria et al. proposed the biologic TNM (bTNM) as a better prognostic 
indicator (Bagaria et al. 2014). The bTNM incorporates the biomarker profile, defined 
solely by the triple-negative phenotype, in the TNM staging system, whereby the stage is 
first determined by TNM, and the addition of the triple-negative phenotype upstages the 
cancer to the next stage. 
The development of primary tumour of breast is a step-wise process that stars with 
a proliferative growth of epithelial cells in a mammary duct, and culminates in invasion 
of surrounding tissue, as explained below. After the initial growth of cells, tumour-
Cancer stage Tumour size 
(T) 
Regional nodal 
involvement 
(N) 
Distant 
metastasis 
(M) 
Description 
Stage I T1 N0 M0 Lesions measure 2 cm or less without 
metastases 
Stage IIA T0 or T1 N1 M0 Lesions measure 2 cm or less with 
involvement of the axillary lymph node 
T2 N0 M0 Lesions measure from 2 cm to 5 cm without 
involvement of the axillary lymph nodes 
Stage IIB T2 N1 M0 Lesions measure from 2 cm to 5 cm with 
involvement of the axillary lymph node 
T3 N0 M0 Lesions measure more than 5 cm 
Stage IIIA T0, T1 or T2 N2 M0 Lesions of any size with metastases in axillary 
lymph nodes (absence of clinically evident 
axillary lymph node metastases) 
T3 N1 or N2 M0 Lesions measure more than 5 cm with or 
without metastases in axillary lymph nodes 
Stage IIIB T4 N0, N1 or N2 M0 Tumour of any size which directly extend to 
the chest wall, skin or lymph nodes 
Stage IIIC Any T N3 M0 Tumour of any size with involvement of the 
axillary and/or internal mammary lymph 
nodes 
Stage IV Any T Any N M1 Presence of distant metastases 
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associated angiogenesis must occur if a malignant mass is to exceed 1 mm in diameter 
(Fidler 2002). The association between angiogenesis and cancer progression was first 
described by Judah Folkman et al., who stated that tumour growing was directly 
dependent of blood vessel network development (Folkman et al. 1971). Angiogenesis is 
stimulated when tumour tissues require nutrients and oxygen, being essential for cell 
viability. In fact, the absence of vascular support can cause the tumour to become necrotic 
or even apoptotic (Nishida et al. 2006). Angiogenesis involves highly regulated paracrine 
signalling between vascular growth factors released by cancer cells and host cells, and 
their respective receptors expressed on endothelial cells (ECs) of preexisting vessels. 
Among the proangiogenic factors expressed by BCCs are vascular endothelial growth 
factors (VEGFs) and angiopoietins, which can be induced through hypoxia inducible 
factor 1α and integrins (Felcht et al. 2012, Raja et al. 2014). On the other hand, ECs begin 
to release specific proteases, such as matrix metalloproteinases (MMPs), to degrade the 
basement membrane (BM) and extracellular matrix (ECM) that surround a nearby 
capillary, thereby facilitating their migration into the malignant mass (Papetti and Herman 
2002). After ECs proliferation, the newly formed capillary is generally leaky due to the 
weak cell-cell junctions between ECs and the vulnerable reconstituted BM that surrounds 
these cells (Shenoy and Lu 2014). Therefore, angiogenesis plays an important role not 
only in BC growth and progression in primary tumour site, but also during the metastatic 
stage of BC. Thence, one of the therapies for solid cancers may involve the use of 
angiogenesis inhibitors, which would consequently block angiogenesis and tumour cell 
growth and may prevent metastasization to distant organs (Brave et al. 2011). 
According to the TNM staging system, when the cancer reaches its most advanced 
or metastatic stage, tumour cells have the ability to spread and form new tumours in 
distant visceral organs such as lungs, liver, and brain, and/or in non-visceral organs that 
include bone, and skin (Berman et al. 2013). The arrest and growth of malignant cells in 
‘target organs’ present a preferential distribution and location, a process called 
organotropism (Lu and Kang 2009). The organotropism depends on the following factors: 
the receptor status of BCCs; the circulatory pattern, despite the fact that the most 
frequently organs metastasized by BCCs do not have an immediate direct vascular 
connection with the primary tissue; genetic signatures present in tumour cells that 
orchestrate and control the metastatic tropism; and the microenvironment of the organ 
that will be metastasized (Minn et al. 2005, Spano and Zollo 2012, St Romain et al. 2012). 
Regarding BC, this cancer represents the second most frequent cause of central nervous 
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system (CNS) metastases, after lung cancer, with metastases occurring in 12-31% of 
patients (Vuong et al. 2011, Saha et al. 2013). 
Brain metastasis is commonly associated with poor prognosis and diminished 
quality of life, being normally a catastrophic life-threat outcome for patients with solid 
cancers, such as BC (Cruz-Muñoz and Kerbel 2011, Jaboin et al. 2013). In fact, the 1-
year survival rate of patients with BC metastatic to the CNS was reported as only 20% 
(Altundag et al. 2007). Moreover, there are no targeted therapies specific for this 
secondary tumour formation, and it is expected that the incidence of brain metastasis 
continues to increase (Clayton et al. 2004, Steeg et al. 2011). In addition, the incidence 
of brain metastasis from the primary breast tumour also increases among patients who 
received chemotherapy or targeted molecular therapeutic such as trastuzumab (Yau et al. 
2006, Tonyali et al. 2016). The causes of this increased incidence of brain metastases are 
unknown, despite the several theories that have been posited. Since the treatment of BC 
improves the patient’s quality of life and survival, the probability of cancer progression 
and hence formation of metastases, particularly in the brain, are also enhanced. On the 
other hand, the brain represents a ‘sanctuary’ organ at risk for disease relapse due to the 
presence of the blood-brain barrier (BBB), a highly impermeable structure that prevents 
CNS penetration of most of the conventional and new chemotherapeutic agents (Tonyali 
et al. 2016). Moreover, glial cells that compose the cerebral microenvironment have a 
profound impact on the efficacy of chemotherapy by upregulating drug resistance, 
antiapoptosis, and survival genes in cancer cells, thus rendering malignant cells resistant 
to therapy (Lee et al. 2016). So, both vascular ECs and brain resident cells protect BCCs 
from chemotherapy. Another hypothesis postulates that the incidence of brain metastases 
only seems to have increased since their detection is facilitated by the increased use of 
refined imaging and the greater attention paid to neurological signs or symptoms (Fink 
and Fink 2013). Therefore, a better knowledge of the determinants of brain 
metastasization is essential for the identification of patients at risk of formation of 
secondary tumour and for the development of novel therapeutic approaches able to 
prevent such effect from occurring and, thus, to improve the clinical outcomes. In this 
review, we present the processes that occur during the course of BCCs from the primary 
tumour site to brain. Furthermore, we explore the still intriguing and unclear mechanisms 
by which these cells are able to cross the BBB and form brain metastasis, which may 
constitute potential therapeutic targets.  
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2. From primary tumour to secondary organ 
Metastasization is a multistep process ranging from the output of cancer cells from 
the primary tumour to their colonization in the ‘target organ’ (Nguyen et al. 2009). 
Among these steps are epithelial-mesenchymal transition (EMT) that facilitates invasion 
of mammary tissue and intravasation into the circulatory system, survival through the 
vasculature, arrest at distant organ sites, extravasation within the secondary organ, and 
finally proliferation and formation of metastasis. When the secondary organ is the brain, 
the extravasation of BCCs requires the interaction between the tumour cell and the brain 
microvascular endothelium that forms the BBB (Wilhelm et al. 2014). Once inside the 
brain, the cells that compose the microenvironment of this secondary organ play a key 
role in promoting proliferation and colonization by metastatic cells, providing crucial 
support for cell survival and tumour growth (Lorger 2012). To complete the invasive-
metastatic cascade, BCCs reacquire their epithelial phenotype via mesenchymal-
epithelial transition (MET), and form well-established brain metastases (Gunasinghe et 
al. 2012). Identifying and understanding all the mechanisms behind the BC 
metastasization into the brain may lead to limiting tumour progression, making all steps 
of the metastatic process potential targets for therapeutic intervention.  
Mammary ducts are lined by columnar or cuboidal epithelial cells, surrounded by 
a discontinuous layer of contractile myoepithelial cells, encircled by the BM, and 
embedded by the ECM (Muschler and Streuli 2010, Owens et al. 2013) that separates 
epithelial and stromal compartments (Fig. 1). So, the morphogenesis and architecture of 
normal mammary epithelium are ensured by cell-cell and cell-BM interactions. Epithelial 
cells establish interactions with neighbouring cells through intercellular junctions that 
include tight junctions (TJs), adherens junctions (AJs), desmosomes, and gap junctions 
(GJs). TJs are located at the apical membrane of epithelial cells and their functions are 
the restraining of paracellular transport, and establishment and maintenance of apical-
basal epithelial polarity (Giepmans and van Ijzendoorn 2009, Owens et al. 2013). These 
junctions are formed by transmembrane proteins occludin, claudins, and junctional 
adhesion molecules, and the cytosolic proteins of the zonula occludens (ZO) family that 
are responsible for the attachment to the cytoskeleton protein actin. AJs are located 
subjacent to TJs, and have a crucial role in providing adherent strength and attaching the 
actin cytoskeleton to the plasma membrane (Giepmans and van Ijzendoorn 2009, Owens 
et al. 2013). These junctions are formed by the transmembrane cadherins, namely 
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epithelial cadherin (E-cadherin), and the cytosolic catenins. Basally to AJs are 
desmosomes that provide mechanical stability by anchoring cytoskeleton keratinous 
intermediate filaments to the plasma membrane and facilitate cell-to-cell communication 
Fig. 1 Schematic representation of the mammary duct and of the alterations occurring 
during the progression of breast cancer (BC). In normal breast, the mammary duct is lined 
by polarized epithelial cells that are surrounded by a discontinuous layer of myoepithelial 
cells, and encircled by a basement membrane (BM); mammary epithelial cells establish 
intercellular junctions between neighbouring cells and with myoepithelial cells, and 
attach to the BM through hemidesmosomes (a); the intercellular junctions are composed 
by tight junction (TJ), adherens junction (AJ), desmosome, and gap junction (GJ), and 
each junction possesses a specific composition and assembly (a1). The duct is embedded 
in the extracellular matrix of the mammary parenchyma. The development of breast 
primary tumour occurs through a step-wise progression from benign flat epithelial atypia 
to atypical ductal hyperplasia, evolves into malignant ductal carcinoma in situ, and finally 
to invasive ductal carcinoma; both flat epithelial atypia and atypical ductal hyperplasia 
are characterized by intraductal proliferation of epithelial cells, resulting in multi-
layering of ductal epithelium (b and c); in ductal carcinoma in situ, there are still tumour 
cells remaining connected by intercellular junctions between neighbouring ones, and this 
type of BC consists of malignant cell masses that lack ductal organization, but remain 
restricted to breast ducts, and are surrounded by both myoepithelial cells and an intact 
BM (d); finally, invasive ductal carcinoma is characterized by an extensive growth of the 
malignant cells beyond the ductal structure and the BM, complete loss of cell-cell 
adhesion between cancer cells, with the exception of the tumour cells that invade the 
surrounding tissue as clusters, reduced number of myoepithelial cells, and breaching of 
BM, which consequently lead to infiltration of the breast ducts by tumour cells and grow 
into the surrounding tissue (e). 
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through signal transmission (Brooke et al. 2012, Owens et al. 2013). The proteins of this 
type of intercellular junctions include transmembrane adhesion proteins (desmoglein and 
desmocollin) that belong to the cadherin family, and cytosolic proteins (desmoplakin, 
plakoglobin, and plakophilin) that form the desmosomal plaque. This cytoplasmic plaque 
is responsible for connecting the cytoskeleton to the transmembrane adhesion proteins 
(Brooke et al. 2012). Desmosomes are also responsible for the attachment of epithelial 
cells to myoepithelial cells (Gudjonsson et al. 2005). Finally, less regularly organized, 
GJs are unique intercellular channels that allow diffusion of small molecules, being 
essential for the communication between neighbouring cells (Giepmans and van 
Ijzendoorn 2009). These channels are composed by the transmembrane proteins 
connexins (Cx), wherein the Cx43 is the most abundantly expressed in humans. Similarly 
to other intercellular junctions, GJs also establish interactions with the cytoskeleton, 
namely through microtubules and actin, which increase GJ stability (Giepmans 2006, 
Giepmans and van Ijzendoorn 2009). Regarding cell-BM interactions, they are 
established by junctional complexes like hemidesmosomes, which anchor the cells to the 
underlying BM, and maintain tissue polarity (Borradori and Sonnenberg 1999). The 
hemidesmosomes are composed by three classes of proteins: the cytoplasmic plaque 
proteins (bullous pemphigoid antigen 1 isoform e and plectin) responsible for the linkage 
of cytoskeleton to the cell surface; the transmembrane proteins [integrin α6β4, bullous 
pemphigoid antigen 2, and cluster of differentiation (CD)151] that act as cell receptors 
connecting the cell and the ECM, and the BM-associated proteins (laminins, such as 
laminin-332) of the ECM (Borradori and Sonnenberg 1999, Walko et al. 2015). In 
mammary duct, hemidesmosomes bind myoepithelial cells to BM (Gudjonsson et al. 
2005). Since the myoepithelial cells form a discontinuous layer, breast epithelial cells can 
also interact with the BM through hemidesmosomes and proteoglycan adhesion 
complexes, whose proteins are coupled to the cytoskeleton and associated to signalling 
pathways that control cell fate (Bergstraesser et al. 1995, Muschler and Streuli 2010). 
Thus, the regulation of cell-cell junction complexes and epithelium polarity ensures 
structural and functional differentiation of the epithelial mammary tissue and their 
deregulation is associated with cancer. In fact, alterations in desmosomes, GJs, and 
hemidesmosomes have been increasingly associated with BC progression (Bergstraesser 
et al. 1995, Brooke et al. 2012, Owens et al. 2013), whereas TJs and AJs are involved in 
the migration of malignant cells across the endothelium (Martin et al. 2002, Arvanitis et 
al. 2014). 
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It is consensual that the development of a primary breast tumour is a multistep 
process, although no consensus has still been reached on the steps and features of each 
stage (Ellis 2010, Bombonati and Sgroi 2011). For the ductal type BC progression, the 
classical ductal model proposes that evolution initiates in normal epithelium, progresses 
from benign flat epithelial atypia to atypical ductal hyperplasia, evolves into malignant 
ductal carcinoma in situ, and finally to invasive ductal carcinoma (Ellis 2010, Bombonati 
and Sgroi 2011), as schematically depicted in Figure 1. In addition to the mentioned 
phases, an alternative model proposes an intermediate step before the progression to flat 
epithelial atypia, a phase called usual ductal hyperplasia (Bombonati and Sgroi 2011). 
However, immunohistochemical and molecular biological evidences strongly support 
that this alternative model of ductal BC progression is likely invalid (Ellis 2010, 
Bombonati and Sgroi 2011). Thus, according to classic ductal model, both epithelial 
atypia and hyperplasia are precursor lesions characterized by intraductal proliferation of 
epithelial cells, resulting in multi-layering of ductal epithelium. Ductal carcinoma in situ 
is the most common type of non-invasive BC. This type of BC is another intraductal 
proliferative lesion characterized by lacking ductal organization, but remains restricted to 
breast ducts without invasion through the BM into the surrounding breast stromal 
compartment (Ellis 2010, Pinder 2010, Bane 2013). The tumour cells that compose the 
primary tumour still express E-cadherin that is progressively lost with disease 
progression, and are surrounded by both a layer of myoepithelial cells and an intact BM. 
Lastly, the invasive ductal carcinoma consists in an extensive growth of the malignant 
cells beyond the ductal structure and the BM (Sgroi 2010). Although still under debate, 
increasing evidence suggests that the progression of carcinoma in situ to the invasive type 
is related to activation of the EMT that allows malignant cells to migrate and escape from 
the primary tumour (Knudsen et al. 2012). So, invasive ductal carcinoma is characterized 
by complete loss of cell-cell adhesion, reduction in myoepithelial cell number, and 
breaching of BM, which consequently lead to infiltration of the breast ducts by tumour 
cells and migration into the surrounding tissue (Gusterson et al. 1982, Debnath et al. 2003, 
Kominsky et al. 2003). Therefore, invasive cells have the potential to spread into 
lymphatic and/or blood vessels and finally form metastases in other organs.  
 
2.1. Epithelial-mesenchymal transition 
To date, the EMT has been the phenomenon that better explains distant metastases 
formation by epithelial cancers, such as BC. EMT is a reversible process whereby an 
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epithelial cell acquires mesenchymal features (Yang and Weinberg 2008), as depicted in 
Figure 2. In contrast to epithelial cells, mesenchymal cells usually are not involved in 
cell-cell interactions and lack the apical-basal polarity (Greenburg and Hay 1982). Thanks 
to these features, mesenchymal cells have a higher invasiveness than epithelial cells. 
Initially, carcinoma cells lose the junctions that join them to other cells and/or to BM. 
Hence, BCCs downregulate the expression of epithelial marks, such as the 
transmembranar E-cadherin and the intermediate filament pan cytokeratin, followed by 
enhanced production of mesenchymal proteins, including neuronal cadherin (N-cadherin) 
and vimentin (transmembrane adhesion molecule and intermediate filament protein, 
respectively) (Onder et al. 2008, Lv et al. 2013). The switch between E-cadherin and N-
cadherin induces the resistance to anoikis, a programmed cell death induced by loss of 
cell adhesion, through the modulation of pro- and anti-apoptotic genes (Onder et al. 2008, 
Paoli et al. 2013). Thus, the ability to overcome anoikis is correlated with the acquisition 
of the mesenchymal phenotype, allowing the survival and proliferation of cancer cells 
without cell-cell interactions. In addition, activation of EMT is accompanied by a 
breakdown of the BM due to increase of protease secretion, such as MMPs, and 
alterations in the production of BM proteins (Tester et al. 2001, Ota et al. 2009, Espinosa 
Fig. 2 Schematic representation of epithelial-mesenchymal transition (EMT), a process by 
which epithelial breast cancer cells acquire mesenchymal characteristics. Mammary 
epithelial cells are connected to each other through intercellular junctions (tight junctions, 
adherens junctions, desmosomes, and gap junctions), as well as to the basement membrane 
(BM) by hemidesmosomes. During EMT, mammary epithelial cells lose cell adhesion and 
polarity, and consequently stability, acquiring invasive ability. Along this process, the 
expression of epithelial proteins is decreased, whereas that of mesenchymal proteins is 
increased, the morphology changes from cuboidal/cylindrical to fusiform. In parallel with 
the changes in the morphogenesis and architecture of the mammary ducts, the BM 
undergoes disruptive changes. 
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Neira and Salazar 2012). These alterations lead to a loss of polarity, a reorganization of 
cytoskeletal constituents, and an acquisition of mesenchymal-like phenotype, essential 
for their entry into blood or lymphatic stream.  
Although EMT allows malignant cells to change their shape and motility, not all 
BCCs complete this process, retaining certain epithelial characteristics. This fact is 
supported by the co-expression of mesenchymal and epithelial markers in BCCs, allowing 
them to have simultaneously adhesion and migratory properties (Yu et al. 2013). In 
addition, oestrogen binding to ER also promotes intercellular adhesion via upregulation 
of the desmosomal proteins and enhancement of formation of desmosomes (Maynadier 
et al. 2012), increasing the cell-cell attachments that allow tumour cells to move and 
invade collectively. Thus, some malignant cells can form multicellular clusters even in 
primary tumour mass. Collective migration of grouped cells that maintain their cell-cell 
interactions has been implicated in cancer metastasis, and may favour the survival of BCC 
clusters in circulation. Once in the circulatory system, cancer cells are called circulating 
tumour cells (CTCs) and can be detected as single cells and as multicellular clusters 
termed as tumour emboli (Bidard et al. 2010, Tsoi et al. 2010). Both individual and 
clusters of CTCs can interact with platelets, which protect the malignant cells against the 
immune response (Gay and Felding-Habermann 2011, Roop et al. 2013). Such interaction 
with platelets also enhances chemotaxis and chemoinvasion, and posteriorly facilitates 
extravasation. However, since CTCs are probably targets of a selective process 
responsible for eliminating carcinoma cells with a lower metastatic potential, the tumour 
embolus presents a higher ability to form new tumours compared to an individual cell 
(Aceto et al. 2014). Due to their higher dimensions and resistance to apoptosis compared 
to an individual cell, multicellular clusters are more likely not only to survive during the 
way up to the organ that these cells will metastasize, but also to be trapped in small 
capillaries of secondary sites. 
Regardless of the type of EMT, many genes are transcriptionally altered in order 
to coordinate the repression of epithelial proteins. This repression is orchestrated by 
regulators such as the transcription factors Twist, Snail (zinc finger protein snail 1), Slug, 
and ZEB (zinc finger E-box-binding homeobox) family (Samatov et al. 2013). Among 
the EMT transcription factors, Twist has the ability to promote the formation of 
invadopodia, specialized actin-based membrane protrusions found in malignant cells that 
facilitate the local invasion through focal ECM degradation (Eckert et al. 2011). In 
addition, the regulators of EMT mediate several signal transduction pathways, including 
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transforming growth factor beta (TGF-β) and Notch1 signalling, which in turn promote 
metastasization.  
So, during the transition from in situ to invasive BC, the primary tumour cells 
exhibit mesenchymal characteristics that allow them to survive without cell-cell 
interactions and to degrade the BM, resulting in migration and local invasion of mammary 
tissue. 
 
2.2. Local invasion 
Invasion is one of the main processes of metastatic cascade, being not only a 
fundamental step in tumour progression, but also a driving force for metastasis. In ductal 
carcinoma in situ, the cancer cells reside within a primary tumour site well-confined by 
myoepithelial cells and a BM that oppose tumour growth and invasion (Sternlicht et al. 
1997, Hu et al. 2008). However, when the tumour progresses to an invasive form, the 
number of myoepithelial cells reduces at sites of invasion, becoming the minor 
component of invasive ductal carcinomas (Gusterson et al. 1982). In addition, malignant 
cells undergoing EMT induce the secretion of proteases that are responsible for degrading 
the BM. This component of mammary gland plays an important role in invasion of BCCs, 
since the BM is a reservoir of growth factors that are released during its degradation by 
tumour cell-secreted proteases (Vukicevic et al. 1992, Hu et al. 2008). Moreover, the BM 
also plays pivotal roles due to its involvement in pathways initiated by integrin-mediated 
cell-matrix adhesions that induce intracellular signals and lead to alterations in cell 
polarity, survival, proliferation, and migration (Nisticò et al. 2014). In addition to 
myoepithelial cells and BM, even normal mammary epithelial cells promote the invasion 
of neighbouring tumour cells by secreting soluble laminin, a BM protein, as recently 
suggested (Lee et al. 2015). The continuous production of laminin induces long 
membrane cellular protrusions in BCCs, which in turn allow the contraction and 
subsequently invasion of the surrounding matrix by malignant cells. So, although the 
precisely controlled tissue architecture of normal epithelium serves as an intrinsic barrier 
to invasiveness, this may be not enough to stop the cascade that will culminate in 
metastasization of a secondary site. 
Tumour cells can have a diversity of invasive strategies, which are closely related 
to EMT. When a cancer cell undergoes a complete EMT and acquires the mesenchymal 
phenotype, this cell invades singly into the surrounding tissue. However, as mentioned 
above, some malignant cells maintain epithelial characteristics, preserving cell-cell 
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junctions, and this strategy allows the BCC cluster to invade and migrate collectively. 
These two different strategies of invasion can also coexist within the same tumour (Friedl 
et al. 1995). Curiously, cancer cells can also undergo transition between invasion modes 
through the switch between activation and blockade of TGF-β signalling associated to 
single cell movement and collective cell invasion, respectively (Giampieri et al. 2009). 
Regardless of the chosen strategy of invasion, the proteolytic destruction of the BM is 
essential for migration and invasion of tumour cells. Once motile BCCs have dissolved 
the BM, they enter in mammary stroma where they interact with stromal cells that 
facilitate the tumour progression.  
In normal morphogenesis, mammary ducts are surrounded by the stroma formed 
by the ECM and a wide variety of cell types, including adipocytes, fibroblasts, and 
macrophages (Sternlicht et al. 2006). The ECM is the major component of mammary 
gland microenvironment and, similarly to the BM, regulates epithelial architecture and 
function (Muschler and Streuli 2010). The cancer progression is dependent on the 
remodelling and stiffening of the ECM surrounding the tumour cells (Levental et al. 2009, 
Ko et al. 2016). The remodelling of this matrix is associated to a crosslinking of collagen 
(the most abundant ECM scaffolding protein), which in turn stiffens the ECM, promotes 
focal adhesion, and induces invasion and tumour progression (Levental et al. 2009). In 
addition, aggressive malignant cells are able to alter the mechanical environment of the 
matrix through the secretion of bioactive lipids that increase ECM stiffness (Ko et al. 
2016). Moreover, carcinoma cells release MMPs, such as MMP-2 and MMP-9, that 
degrade the ECM and augment the bioavailability of ECM-derived growth factors (Tang 
et al. 2005). One of these growth factors is VEGF that attracts ECs to migrate into areas 
of active tumour cell proliferation, where cancer cell-induced cleavage of ECM 
components results in increased vascularization (Lee et al. 1998, Tang et al. 2005). In 
addition, the degradation of ECM components by invasive tumour cells can lead to an 
extensive endothelial anoikis, and to attraction and migration of metastatic cells through 
apoptotic endothelium (Peyri et al. 2009). Thus, deregulation of ECM stiffness and 
dynamics enhances cancer cell survival, proliferation, migration, and invasion, playing 
an essential role in BC progression. Besides ECM, stromal cells also have an important 
role in invasion. Regarding adipocytes, the crosstalk and interaction between these 
stromal cells and malignant cells lead to an activated phenotype in adipocytes, named 
cancer-associated adipocytes (Dirat et al. 2011). In turn, this activation results in 
overexpression of proteases and proinflammatory cytokines by adipocytes that stimulate 
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the invasiveness of tumour cells. Curiously, adipose cells can also promote the resistance 
of BCCs to cellular cytotoxicity by therapies such as trastuzumab (Duong et al. 2015), 
thus ensuring that the malignant cells continue to invade the breast tissue. Local invasion 
leads to the proximity of cancer cells and adipocytes, which respond to this proximity by 
phenotypical changes that generate fibroblast-like cells (Bochet et al. 2013). The 
fibroblasts are stromal cells whose functions are maintaining the mammary ECM intact 
through the synthesis of ECM components, such as collagens, proteoglycans and 
fibronectin, and regulating the differentiation and homeostasis of adjacent epithelia 
(Kalluri and Zeisberg 2006, Inman et al. 2015). In tumour stroma, BCCs recruit and 
activate the majority of fibroblasts, termed as cancer-associated fibroblasts, which result 
in ECM remodelling to create tracks for tumour cell migration (Gaggioli et al. 2007, 
Avgustinova et al. 2016). The generation of cancer-associated fibroblasts depends on 
TGF-β signalling in response to Wtn7a, a factor secreted by aggressive malignant cells 
that drives the acquisition of a desmoplastic response (Avgustinova et al. 2016). Host 
macrophages are phagocytic cells that have an important role in host defence against 
pathogens (Paape et al. 2000) and, like the other stromal cells, also participate in local 
invasion. This initial step of BC progression depends on both paracrine signalling with 
macrophages as well as autocrine signalling involving the tumour cells themselves 
(Patsialou et al. 2009). On one hand, macrophages secrete epidermal growth factor (EGF), 
which promotes the formation of elongated protrusions that guide malignant cells toward 
blood vessels, this way favouring the invasion process (Goswami et al. 2005, Wyckoff et 
al. 2007). On the other hand, tumour cells secrete the cytokine colony-stimulating factor, 
and sense and stimulate EGF secretion by macrophages. Thus, all stromal components 
contribute, directly or indirectly, to the movement of BCCs toward lymph nodes and 
blood vessels, as will be addressed below.  
Dynamic interaction between cancer cells and the surrounding microenvironment 
of mammary ducts is essential to potentiate the malignant behaviour of carcinoma cells. 
Since the influence exerted by the stromal components remains largely unknown, detailed 
characterization of these components will provide further evidence of their critical roles 
in BC progression. However, it is unquestionable that the interactions between cancer 
cells and the surrounding microenvironment are essential for their entry into the stroma 
of mammary gland and move directly towards the systemic circulation. Once near a blood 
or lymphatic vessel, intravasation of tumour cells can occur and, if they survive in 
circulation, dissemination to distant sites may take place. 
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2.3. Intravasation 
As mentioned above, malignant cells detach from the primary tumour mass by 
undergoing EMT and then invade the surrounding microenvironment of mammary duct; 
once in the stroma of the mammary gland, the stromal components, such as fibroblasts 
and macrophages, guide the cancer cells towards vessel wall. The subsequent entry of 
cancer cells into the circulatory system is called intravasation (Wyckoff et al. 2000). 
Cancer cells can escape from the primary tumour via two main routes of dissemination: 
haematogenous or lymphatic (Markiewicz et al. 2013). The decision to intravasate into 
either blood or lymphatic vessels may depend on the following factors: anatomical 
differences of the blood and lymphatic vessels; invasion strategy utilized by tumour cells 
(individual movement versus collective migration); movement promoted by stromal cells; 
active mechanisms that attract cells to a specific type of vasculature; induction of 
angiogenesis and/or lymphangiogenesis; and the effect of fluid shear stress on cell 
survival in circulation (Wong and Hynes 2006, Bockhorn et al. 2007).  
Although both blood and lymphatic vessel walls are lined by ECs, there are 
anatomical differences between them that may influence the intravasation of the 
malignant cell. Similarly to epithelial cells, the ECs of blood vessels are also connected 
by cell-cell junctions although lacking desmosomes (Wallez and Huber 2008). These ECs 
are embraced by some pericytes, perivascular cells that wrap around blood capillaries and 
reinforce vascular structure, and both ECs and pericytes are embedded within the BM 
(Fujiwara and Uehara 1984, Davis and Senger 2005). Thence, the anatomical barriers of 
blood vessels appear to be more hardly penetrated by individual cancer cells. Thus, when 
the intravasation occurs through the blood vessels, invasive cells must induce cellular and 
molecular changes to promote their cross through BM, pericyte, and EC barriers. In 
contrast, ECs that compose the lymphatic capillaries lack tight intercellular junctions, are 
not embraced by pericytes, and are surrounded by a discontinuous BM (Tanis et al. 2001). 
Indeed, the higher permeability of lymphatic vessels may favour the passage of individual 
and mainly clusters of tumour cells (Byers et al. 1995). Despite the migration of cancer 
cell clusters through blood vessels has not been described, the observation of tumour 
emboli in bloodstream of BC patients (Tsoi et al. 2010) raises two hypotheses: whether 
cancer cells intravasate under the form of clusters or, once in bloodstream, aggregate with 
components and cells present in blood circulation. In addition, stromal cells of 
surrounding microenvironment can promote a preferential movement of carcinoma cells 
to blood vessels, since the interaction between cancer cell and stromal ones to promote 
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lymphatic intravasation has never been reported. Like local invasion, the haematogenous 
intravasation is facilitated by macrophages. Macrophages occupy a perivascular 
localization in vessel surface, and tumour cells are attracted by the macrophage-derived 
EGF (Wyckoff et al. 2007). This attraction probably explains why malignant cells are 
more likely to migrate toward blood vessels than lymphatic vessels in mammary tumours. 
In addition, macrophage-derived VEGF-A, a growth factor that induces EC proliferation 
and promotes cell migration, causes local disruption of EC junctions, which hence leads 
to transient vascular permeability of the blood vessel (Harney et al. 2015). Thus, the 
interaction between perivascular macrophages and BCCs forms chemoattractive 
gradients that augment the recruitment of malignant cells towards the blood vessel wall, 
and facilitate the transendothelial crossing through vascular endothelium. The availability 
of blood and/or lymphatic vessels in the surrounding area of tumour cells may also 
influence the pathway taken for dissemination. Both angiogenesis and lymphangiogenesis 
are induced by the same growth factors, such as VEGFs (Alitalo et al. 2005, Shibuya 
2006). Hence, tumours might concomitantly induce angiogenesis and 
lymphangiogenesis; however, lymphangiogenesis has been less documented in BC 
compared to angiogenesis (Wong and Hynes 2006). Finally, the fluid shear stress plays a 
pivotal role in cell survival within the circulation and differs between bloodstream and 
lymphatic stream. Whereas tumour cell survival may benefit from the low-shear system 
of fluid transport characteristic of lymphatic vessels, the increased haemodynamic flow 
rate may also help individual cells to reach distant organs (Byers et al. 1995). Thus, the 
dissemination via the haematogenous circulation appears to represent the major 
mechanism by which invasive BCCs are able to spread and form secondary tumours.  
The intravasation through blood vessels occurs in the abluminal to luminal 
direction and involves important interactions between the invasive cancer cell and the EC 
that composes vessel walls, as schematically depicted in Figure 3. Although the 
intravasation is considered one of the key steps of the metastatic cascade, this interaction 
between tumour cells and ECs remains poorly characterized, not only because the 
transendothelial migration (TEM) is a localized and transient process, but also because 
the in vitro models used to study this process are only useful to understand and identify 
molecular components and signalling pathways involved in intravasation (Khuon et al. 
2010). Prior to TEM, adhesion of cancer cell to EC must occur to approach these two 
cellular types and facilitate the translocation of the tumour cell into the circulation. 
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Curiously, the cell surface adhesion receptors expressed by vascular and lymphatic ECs 
Fig. 3 Schematic representation of the transendothelial migration (TEM) pathways during 
the intravasation process. Breast cancer cell (BCC) can cross endothelial cells (ECs) to 
enter into the blood circulation by paracellular or transcellular routes. This is a multistep 
process that involves interactions between BCC and ECs through the binding of specific 
ligands to the corresponding receptors. Vascular ECs express membrane receptors such 
as cluster of differentiation (CD)31, endothelial selectin (E-selectin), and integrin β1 that 
interact with the respective ligand integrin αvβ3, CD44, and integrin β1 expressed by 
BCC. The adhesion step approaches the cancer cell to the vascular endothelium and 
facilitates the TEM. During paracellular migration, there is a disruption and 
reorganization of intercellular junctions and also a reorganization of EC cortical actin 
cytoskeleton around the invasion site. The ectodomain shedding, a mechanism that 
compromises the integrity of cell-cell junctions, of the adherens junction protein vascular 
endothelial (VE)-cadherin is promoted by a disintegrin and metalloproteinase 
(ADAM)12, and the phosphorylation of this protein is induced by both adhesion step via 
integrin β1 and reactive oxygen species (ROS). In addition, adhesion via integrin β1 
promotes the dissociation of β-catenin from the VE-cadherin/catenin complex. Regarding 
tight junctions (TJs), the hepatocyte growth factor/scatter factor (HGF/SF), a cytokine 
secreted by stromal cells, interacts with its receptor, HGFR, expressed in ECs surface. 
The interaction between HGF/SF and HGFR reduces the expression of the TJ proteins 
claudin-1, occludin, and zonula occludens (ZO)-1, but not of junctional adhesion 
molecules (JAMs) and claudin-5. On the other hand, during transcellular migration, the 
border of the EC remains intact since the migration of BCC occurs when the EC 
envelopes the malignant one. Firstly, there is a reorganization of the EC actin filaments 
that circumscribe the invasion pore. Then, EC myosin organizes into a ring-like invasion 
array via activation of endothelial myosin light chain kinase (MLCK). This enzyme 
phosphorylates its myosin light chain (MLC), leading to myosin contraction. Thus, the 
rapid cytoskeletal and membrane remodelling creates a transitory pore-like structure that 
encapsulates the BCC and facilitates its migration across the EC. 
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are different (Dua et al. 2005), limiting the process of intravasation and consequently 
haematogenous or lymphatic dissemination only to cancer cells that express the 
respective ligands. Among the membrane receptors expressed by vascular ECs are the 
CD31 (also known as platelet endothelial cell adhesion molecule-1, PECAM-1), 
endothelial selectin (E-selectin), and integrin β1, which interact respectively with integrin 
αvβ3, CD44, and integrin β1 expressed by BCCs (Price et al. 1996, Bauer et al. 2007, Zen 
et al. 2008, Romagnoli et al. 2014). Once the adhesion interactions are established 
between both endothelial and cancer cells, the BCC is able to migrate across the vascular 
endothelium. So far, TEM of BCCs was reported to occur by two types of pathways, both 
supported by ECs: paracellular, i.e. passage through the intercellular junctions of two 
ECs, and transcellular, a transport through the body of an EC that is also called 
transcytosis (Khuon et al. 2010, Arvanitis et al. 2014). Thus, the paracellular migration 
requires the interaction of cancer cells with endothelial junctions to cross the endothelium. 
Firstly, cancer cells interact with AJs, due to their basal localization, and then with TJs. 
During paracellular migration, there is a clear disruption of the AJs protein vascular 
endothelial (VE)-cadherin and reorganization of EC cortical actin cytoskeleton around 
the invasion site to facilitate the transmigration (Arvanitis et al. 2014). The ectodomain 
shedding of VE-cadherin is one mechanism that rapidly releases membrane-anchored 
proteins from the cell surface and converts into soluble proteins (Hayashida et al. 2010, 
Fröhlich et al. 2013), leading to disruption of the AJs. This mechanism is mediated by a 
cell-surface protease that is expressed in vascular ECs, a disintegrin and 
metalloproteinase (ADAM) 12. In addition, both tyrosine phosphorylation of VE-
cadherin and dissociation of β-catenin from the VE-cadherin/catenin complex are 
triggered by adhesion via integrin β1 (Haidari et al. 2012). On the other hand, the 
generation of reactive oxygen species resulting from the interaction of BCC with vascular 
ECs can also induce phosphorylation of VE-cadherin (Haidari et al. 2013). Regarding 
TJs, although there are no apparently changes in distribution or expression of both 
junctional adhesion molecules and claudin-5, the expression of claudin-1, occludin, and 
ZO-1 is reduced, leading to a decreased transendothelial resistance and an increased 
paracellular permeability (Martin et al. 2002). This increased paracellular permeability is 
induced by the hepatocyte growth factor/scatter factor, a cytokine secreted by stromal 
cells that is involved in cancer cell migration and invasion. The hepatocyte growth 
factor/scatter factor requires activation by hepatocyte growth factor activator expressed 
in large amounts by invasive BCCs, and then interacts with the hepatocyte growth factor 
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receptor (also known as c-Met) expressed in ECs surface (Martin et al. 2002, Sierra and 
Tsao 2011). Besides the migration between two adjacent vascular ECs, BCCs were 
reported to cross the endothelial barrier through individual ECs (Khuon et al. 2010). In 
contrast to paracellular pathway, during transcellular migration, the border of the EC 
remains intact since the migration of cancer cell starts to occur when the EC begins to 
envelope the invasive cell (Arvanitis et al. 2014). As transcellular TEM progresses, the 
malignant cell migration requires drastic reorganization of EC actomyosin system, a 
complex composed by both actin and myosin filaments that plays an important role in 
cell contractility (Khuon et al. 2010, Arvanitis et al. 2014). Firstly, at invasion site, there 
is a local reorganization of the EC stress fibres, the major contractile structures constituted 
by actin filaments denuded of myosin, to circumscribe the invasion pore. Some of these 
stress fibres eventually undergo stress-induced fracture and recoil to form a much larger 
pore (Arvanitis et al. 2014). Secondly, EC myosin organizes into a ring-like invasion 
array via localized activation of endothelial myosin light chain kinase (Khuon et al. 2010, 
Arvanitis et al. 2014). This enzyme phosphorylates its myosin light chain, leading to 
myosin contraction. Subsequently, the rapid cytoskeletal and membrane remodelling 
creates a transitory pore-like structure that encapsulates the invading cancer cell and 
facilitates its migration across the EC (Khuon et al. 2010). As the tumour cell passes the 
invasion site, the EC cytoskeleton progressively returns to its initial organization 
(Arvanitis et al. 2014). Thus, intravasation of malignant cells within circulation system is 
a host-tumour interaction, where the endothelium plays a pivotal role in tumour invasive 
potential. 
So, after the BCCs acquire the ability to infiltrate the mammary duct and invade 
the surrounding microenvironment, these cells have the opportunity to enter into the 
circulatory system. Cancer cell intravasation can be considered a rate-limiting step of the 
metastatic process, regulating the number of malignant cells that cross the vascular 
endothelium. Once within the circulatory system, invasive cancer cells migrate out of the 
primary tumour site until reaching the vasculature of the secondary organs where they 
will form new tumours. In order to spread, malignant cells must survive during their 
journey within the bloodstream. 
 
2.4. Survival in circulation 
The microenvironment within the bloodstream and the wide distance between the 
mammary gland and a distant secondary organ are hostile for CTCs, turning their survival 
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into a great challenge. Firstly, the fluid shear stress and increased haemodynamic flow 
rate of the bloodstream, as well as the presence of immune cells especially natural killer 
cells, can result in death of a great proportion of tumour cells. Conveniently, carcinoma 
cells have the ability to escape from immune cell-induced death through cooperative host-
tumour interactions (Labelle and Hynes 2012). Regarding natural killer cells, BCCs are 
able to induce the reduction of function of these immune cells (Mamessier et al. 2011). 
The decreased function of natural killer cells is associated with a decreased expression of 
their activating receptors and an increased expression of inhibitory receptors. In addition, 
tumour cells can benefit from the rapid coating provided by platelets, forming a cluster 
that protects the BCCs from cytotoxicity mediated by natural killer cell antitumour 
reactivity (Kopp et al. 2009). The interaction between platelets and carcinoma cells is 
induced by the expression of cell adhesion molecules in platelets, which bind to cell 
surface molecules expressed by malignant cells (Aigner et al. 1997, Kopp et al. 2009). 
Thus, platelet-coated cancer cells are more likely to persist within the circulation until 
they arrest at distant tissue vasculature, an event whose occurrence may be further 
increased due to the large diameter of the tumour cells.  
The amount of time that malignant cells spend in circulation is believed to be short 
(Aceto et al. 2014), not only because these cells are subjected to shear stress and immune 
cells that eliminate carcinoma cells with a lower metastatic potential, but also because 
CTCs, especially clusters, are rapidly entrapped within capillaries of distant organs. 
Indeed, given the relatively large diameters of BCCs (12–17 µm) (Yusa et al. 2014) and 
the diameter of a capillary (3–30 μm) (Sarveswaran et al. 2016), it is likely that a vast 
majority of tumour cells become trapped in smaller capillaries. In addition, the size of the 
individual cells and clusters of cells is inversely proportional to velocity of cells in 
bloodstream (Au et al. 2016). Thus, aggregates of cancer cells transit in blood vessels at 
low velocity compared to single cells, which increases the probability of their entrapment 
in vessels even with larger diameters. Therefore, it is crucial to understand all the 
mechanisms behind the formation of these clusters to prevent the aggregation of 
malignant cells and/or their entrance into the ‘target organ’. 
After intravasation, survival of cancer cells into the circulation is a crucial step for 
tumour cells, since most of them fail to remain viable. So, only malignant cells with high 
metastatic potential survive and succeed in extravasation and dissemination into other 
organs, such as the brain. 
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3. Brain metastasization 
Breast to brain metastasis follows a vascular distribution mainly through 
haematogenous spread (Lin et al. 2004). The distribution of brain metastasis depends on 
blood flow and tissue volume, being detected 52-62% in the cortex, 30% in central brain 
(which includes hypothalamus, thalamus, midbrain, caudate putamen, ventral striatum, 
and basal forebrain), 5-13% in posterior brain (which includes cerebellum, pons, and 
medulla), and 4% in olfactory regions (Perera et al. 2012). Commonly, BC patients with 
brain metastases exhibit multiple tumours, although they can also present solitary and/or 
leptomeningeal metastases (Evans et al. 2004). The formation of these secondary tumours 
can lead to an impairment of neurocognitive functions related to executive function, 
motor dexterity, and learning/memory (Chang et al. 2007), which may be a consequence 
of interactions between cancer cells and host cells that compose the brain 
microenvironment and the occupation of brain areas responsible for those functions by 
well-established metastases that can reach 4 cm of diameter. 
The arrival of viable malignant cells to the brain can result simply from a physical 
trapping of CTCs in small blood vessels of this secondary organ or from a trapping 
facilitated by migration of tumour cells driven by organ-derived chemoattractants 
(Hujanen and Terranova 1985, Kienast et al. 2010). Chemokines and their receptors play 
a key role in organ-specific metastasis development and one of the most studied pairs is 
the cysteine-X amino acid-cysteine receptor 4 (CXCR4) and its ligand stromal cell-
derived factor-1α (also known as CXCL12) (Müller et al. 2001, Lee et al. 2004, Salmaggi 
et al. 2014). The chemokine CXCL12 is synthetized by brain microvascular ECs 
(BMVECs) to attract CXCR4-positive cells, such as BCCs (Müller et al. 2001, Liu et al. 
2014). In addition, CXCL12 increases vascular permeability, leading to blood vessel 
instability and consequently allowing the TEM through brain endothelium (Lee et al. 
2004). Thus, CXCL12/CXCR4 axis plays an important role in the homing of carcinoma 
cells from primary to secondary site, contributing to metastatic progression. 
Once reaching the ‘target organ’, CTCs arrest within the brain vasculature in small 
capillaries, especially at vascular branch points, where the slower flow allows the 
interactions with BMVECs and posterior extravasation (Kienast et al. 2010, Stoletov et 
al. 2010). Both arrest and extravasation of cancer cells are followed by early, immediate, 
and drastic changes in the brain microenvironment, which promote the growth of 
metastatic tumour cells and their progression to well-established metastasis (Lorger and 
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Felding-Habermann 2010). Since the secondary organ is the brain, the first host cell type 
that extrasavating cancer cells encounter is the BMVEC that composes the BBB (Wilhelm 
et al. 2014). Although this highly selective barrier limits the penetration of both solutes 
and cells due to its elaborate intercellular junctions together with low pinocytic vesicles, 
the evidence that some metastatic cells can cross the BBB is the formation of metastases 
in the brain. The BCCs preferentially metastasize to this secondary organ probably due 
to the fact that, once inside the brain, the BBB not only protects them from the immune 
surveillance of the organism and from chemotherapeutic drugs, but also produces 
substances favourable for their survival and subsequent proliferation. Accordingly, the 
development of brain metastasis has been also correlated with the aggressiveness of BCCs 
(Yonemori et al. 2010). Whereas triple-negative cancer cells are more aggressive and 
have the ability to induce the disruption of the BBB, the HER2-positive cells may develop 
brain metastasis based on their potential to migrate through ECs, maintaining the BBB 
properties. The integrity of BBB is also directly associated to the size of brain lesions 
(Zhang et al. 1992). In fact, in an in vivo brain metastasis model, when BCCs form lesions 
smaller than 0.1 mm2, the BBB remains intact; however, when metastatic tumour mass 
exceeds 0.5 mm2, the large size of these metastases also compromised structurally and 
functionally the BBB. In addition, the increased permeability of BBB can result from the 
disturbance of interactions established between BMVECs and astrocytes caused by 
increasing growth of the tumour mass (Zhang et al. 1992). Thus, although tumour cells 
can induce the BBB disruption, the integrity of this barrier might remain intact or even 
be repaired after the passage of metastatic cancer cells into the brain. 
As mentioned above, the arrest of cancer cells in brain capillaries precedes the 
extravasation of these cells into the ‘target organ’. The migration of malignant cells across 
the brain endothelium is a process highly dependent on interactions established between 
tumour cells and the BBB endothelium. When the extravasation of carcinoma cells occurs 
successfully, these cells can proliferate and colonize the brain giving rise to the formation 
of new tumours. 
 
3.1. Extravasation and role of the blood-brain barrier 
Intravasation and extravasation are two similar processes, since both require the 
TEM of BCCs across the EC barrier. However, the approach to the endothelium by 
malignant cells is from opposite sides of vasculature. The extravasation of BCCs is the 
passage of highly metastatic CTCs from the bloodstream into the brain through the BBB. 
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Localized between peripheral circulatory system and the neural tissue, the BBB controls 
the cerebral homeostasis, and protects the CNS against neurotoxicity and entry of 
pathogens (Ghersi-Egea et al. 1995). This barrier is composed by BMVECs that establish 
interactions with each other through elaborate intercellular junctions that restrict the 
paracellular permeability (Cardoso et al. 2010). However, the formation of brain 
metastasis suggests that the barrier properties of BMVECs are not enough to prevent the 
cross of certain BCCs through the BBB, and hence allow their entrance into the brain.   
There are three steps involved in extravasation of cancer cells into the brain: 
rolling, firm adhesion and, finally, paracellular TEM, as schematically depicted in Figure 
4. Although the duration of in vitro TEM is estimated to be 6 to 18 hours, the entire 
extravasation process requires 3 to 5 days to be completed (Lorger and Felding-
Habermann 2010). For the occurrence of extravasation, cancer cells must slow down, 
arrest in capillaries with a similar diameter to that presented by the cells, and roll along 
BMVECs surface, establishing several receptor-ligand interactions with ECs (Kienast et 
al. 2010, Stoletov et al. 2010). Although CTCs are subjected to shear forces resulting 
from blood flow, they can migrate on the blood vessel wall with or against the flow due 
to the generation of string traction forces and membrane protrusions (Stoletov et al. 2010, 
Spencer and Baker 2016). Thus, during the rolling, malignant cells search for the best site 
for crossing the BBB, and establish transient interactions with BMVECs. Curiously, when 
cancer cells arrest in BMVECs they present an elongated shape that later rounds up, 
enabling the metastatic cells to stretch across the vessel wall (Lorger and Felding-
Habermann 2010). Similarly to leukocyte recruitment to the endothelium, the rolling of 
CTCs is mediated by selectins, in particular by E-selectin and their ligands (Soto et al. 
2014, Mondal et al. 2016). Selectins are not normally expressed on quiescent BMVECs, 
but, when stimulated by inflammatory cytokines secreted by cancer cells or cancer cell-
associated leukocytes, the expression of these adhesion molecules augments in ECs 
surface (Wong and Dorovini-Zis 1996, Kang et al. 2015). At the same time, tumour cells 
express glycoprotein ligands for E-selectin, including platelet selectin glycoprotein 
ligand-1, CD24, and tetrasaccharide sialyl Lewis x (Myung et al. 2011, Soto et al. 2014). 
Once the first interaction between BCCs and ECs is established, firm and stable adhesion 
between these two cellular types can take place. E-selectin also plays an important role in 
this step of extravasation, while binding to other ligands expressed by tumour cells, such 
as CD44 and mucin 1 (Geng et al. 2012, Kang et al. 2015). In addition, the expression of 
adhesion molecules belonging to the superfamily of immunoglobulins, such as  
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Fig. 4 Schematic representation of key steps of extravasation of a breast cancer cell 
(BCC). Rolling, adhesion, and paracellular migration are key steps occurring during 
metastasization into the brain (a). Rolling and adhesion steps of extravasation allow the 
tight adhesion between BCC and brain microvascular endothelial cells (BMVECs) in 
order to facilitate the subsequent migration across the blood-brain barrier (BBB). The 
elongated tumour cell circulates in the bloodstream. When trapped in small capillaries, 
the BCC rolls along the endothelium until it finds the best location for crossing the BBB, 
and attaches to BMVECs. Rolling and adhesion are dependent on pairs of ligands and 
receptors expressed by both BCC and BMVECs; firstly, BCC expresses ligands, such as 
platelet selectin glycoprotein ligand-1 (PSGL-1), cluster of differentiation (CD)24, and 
sialyl Lewis x (sLex), which interact with endothelial selectin (E-selectin) present in 
BMVECs surface; during adhesion to brain endothelium, there is an increased expression 
of CD44 and mucin 1 (MUC1) in BCC, which interact with E-selectin expressed by 
BMVECs, and integrins that interact with intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1); in addition, MUC1 also binds to 
ICAM-1 (b). The penetration across the BBB into the brain occurs via paracellular 
migration, and requires a rearrangement of occludin, claudin-5, and zonula occludens 
(ZO)-1, and a reduction of junctional adhesion molecule (JAM)-B due to proteolysis by 
cathepsin S; regarding adhesion junctional proteins, there is a displacement and 
disruption of vascular endothelial (VE)-cadherin/catenin complex; in addition, BCC 
secretes 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), which promotes BMVECs 
retraction (c). 
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intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1), is induced by cytokines and increases on BMVEC membranes (Dufour et al. 
1998, Lorger et al. 2011). While ICAM-1 interacts with mucin 1 and integrin αLβ2 (also 
known as lymphocyte function-associated antigen 1), VCAM-1 binds to integrin α4β1 
(also called very late antigen 4) (Geng et al. 2012, Soto et al. 2014). Therefore, all 
receptor-ligand bonds tightly attach the malignant cell to the BMVEC, and consequently 
facilitate the migration of the first one.  
Although the adhesion process described above has focused on cancer cell-
BMVEC interaction, blood components, such as platelets as well as neutrophils, can also 
facilitate the adhesion of metastatic cells to the brain endothelium. First of all, besides the 
fact that platelets shield malignant cells against shear forces and/or against recognition 
and lysis by immune cells (Nieswandt et al. 1999, Palumbo et al. 2005), platelets also 
have a potential role in promoting the adhesion of BCCs to the brain endothelium 
(Felding-Habermann et al. 2001). The interaction between cancer cells and platelets leads 
to activation of integrin αvβ3 in tumour cells, which in turn can interact with integrin 
αvβ3 highly expressed by BMVECs (Felding-Habermann et al. 2001, Vogetseder et al. 
2013). On the other hand, BCCs can establish cell-cell interactions with blood cells, such 
as neutrophils, even before extravasation (Wu et al. 2001, Lorger and Felding-Habermann 
2010). Regarding neutrophils, tumour cells use the adhesion molecules of these blood 
cells to bind to them, and facilitate the adhesion to the vascular endothelium. Neutrophils 
express integrin β2 that binds to its ligand ICAM-1 present on membranes of both 
malignant cells and ECs (Wu et al. 2001, Strell et al. 2007, Lorger et al. 2011). Indeed, 
neutrophils potentiate the TEM of cancer cells by serving as linking cells, allowing the 
anchoring of BCCs to the brain vascular endothelium. So, the host cells, such as 
neutrophils, as well as platelets present in blood circulation are also important for the 
progression of invasive-metastatic cascade and particularly for adhesion prior to TEM. 
The last step of extravasation is the paracellular TEM across the BBB. As 
mentioned above, cancer cells can cross the blood vessel wall by paracellular and 
transcellular routes. However, in in vitro models of the BBB, the paracellular migration 
is the most TEM route used by cancer cells to cross the brain endothelium, and 
consequently the most studied migration route (Rodriguez et al. 2014, Fan and Fu 2016, 
Vandenhaute et al. 2016). During paracellular migration, metastatic cancer cells interact 
with endothelial junctions, firstly with TJs and then with AJs, contrarily to what occurs 
in intravasation. This interaction induces the opening of the intercellular junctions to 
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allow the squeeze of cancer cells between two ECs, and thus their passage through the 
endothelial layer. First of all, the firm adhesion of tumour cell to the endothelium induces 
a partial disruption of endothelial junctions, and finally TEM can completely disrupt these 
junctions (Fan et al. 2011, Fan and Fu 2016). Regarding TJs, the redistribution of 
occludin, claudin-5, and ZO-1 leads to a disruption of this type of junctions, and 
consequently to an increase of BBB permeability (Avraham et al. 2014, Rodriguez et al. 
2014). In addition, junctional adhesion molecule-B is proteolysed by cathepsin S, a 
tumour-derived cysteine protease expressed in early-stages of brain metastases (Sevenich 
et al. 2014). Concerning AJs, besides the displacement and disruption of VE-
cadherin/catenin complex (Lee et al. 2003, Chen et al. 2013), what occurs to these 
endothelial junctions and their involvement in the brain TEM are still poorly understood. 
Along with the mentioned mechanisms, the production and secretion of 12(S)-
hydroxyeicosatetraenoic acid by BCCs may also induce retraction of BMVECs (Uchide 
et al. 2007). This morphological alteration of ECs occurs due to a hyperphosphorylation 
of cytoskeletal proteins such as myosin light chain and actin, and to a rearrangement of 
integrin αvβ3 (Tang et al. 1993). During paracellular migration, the retraction of 
BMVECs and the disruption of their intercellular junctions allow cancer cells to 
incorporate into the EC monolayer, either displacing the ECs or, in some cases, detaching 
these cells completely from the BM (Hamilla et al. 2014). The hypothesis that cancer cells 
may also migrate through the endothelial barrier by transcellular TEM remain to be 
established, but it cannot be discarded. This hypothesis is reasonable, not only because 
the transcellular pathway is described to intravasation process, but also due to the 
existence of TJs that connected the BMVECs that may restrict the intercellular transport. 
However, further studies are required to determine whether this route is used by BCCs to 
extravasate into the brain. 
Regardless of the TEM route used by cancer cells to migrate across the BBB, it 
remains to be established whether the transmigration of tumour cells leaves the brain 
endothelium intact or if it destroys intercellular junctions between ECs. Although the 
endothelial junctions can be disrupted during paracellular migration, it was suggested that 
malignant cells induce local vessel remodelling characterized by clustering of ECs and 
their junctions, a similar mechanism to the one observed during TEM of leukocytes 
(Khuon et al. 2010, Winger et al. 2014). This remodelling of TJs is facilitated by the 
recruitment of membrane from the endothelial lateral border recycling compartment, a 
specific compartment containing adhesion molecules, to seal the intercellular gaps at the 
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exact site of extravasation. Indeed, the absence of any detectable endothelial apoptosis or 
hypoxia at TEM sites suggests that no significant destruction of the BMVECs occurs 
during the extravasation process (Lorger and Felding-Habermann 2010). Taken together, 
this indicates that transmigration of BCCs can occur without causing BBB damage. In 
contrast, several studies have demonstrated that BCCs can increase the permeability of 
BMVECs by inducing changes in TJ proteins, such as claudin-5 and ZO-1, and degrading 
endothelial surface glycocalyx, a structural component of EC monolayer responsible for 
endothelial integrity (Avraham et al. 2014, Rodriguez et al. 2014, Fan and Fu 2016). 
These changes are mediated through an increased endothelial secretion of both 
angiopoietin-2 and tumour necrosis factor alpha, an inflammatory cytokine that also 
induces angiogenesis through the regulation of angiopoietin-2 expression. In addition, 
and similarly to the EMT suffered by epithelial cells, ECs may undergo an endothelial-
mesenchymal transition (EndMT) (Krizbai et al. 2015). This mechanism leads to loss of 
endothelial markers and intercellular contacts between adjacent ECs (such as occludin, 
claudin-5, and VE-cadherin), augment of expression of fibroblast-specific and 
mesenchymal proteins (including N-cadherin, integrin β1, and fibronectin), and 
ultimately differentiation into a myofibroblastic phenotype (Medici and Kalluri 2012, 
Krizbai et al. 2015). The EndMT is stimulated by the TGF-β1 secreted by cancer cells 
and confers contractility to BMVECs facilitating the TEM of BCCs. So, EndMT is an 
additional mechanism that allows extravasation of BCCs towards the brain. These 
findings provide evidence that extravasation into the brain requires mechanisms that are 
not needed during intravasation. 
As in the intravasation, angiogenesis also plays an important role in extravasation. 
In addition to the reduction of TJ and AJ proteins expression, the overexpression of VEGF 
and angiopoietin-2 in BMVECs also results in a disruption of intercellular junctions, 
increasing BBB permeability (Fan et al. 2011, Avraham et al. 2014). This change in 
permeability is induced by the endocytosis of VE-cadherin, which in turn leads to a 
disruption of AJs, as well as by structural damage of TJ. Lastly, the disruption of junction-
associated protein complexes can also be caused by MMPs released by BCCs, such as 
MMP-1, -2, and -9 (Wu et al. 2015, Ko et al. 2016). The MMPs also have an important 
role once cancer cells cross the BMVECs layer, since they degrade the BM. With this 
step, the BCCs extravasation into the brain is completed.  
Since the growth in the primary tumour site until the end of extravasation, 
numerous obstacles and barriers have been already overcame by the cancer cell. Similarly 
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to intravasation, extravasation at distant organ sites can also be considered a rate-limiting 
step of metastatic process, only allowing the passage of a reduced number of malignant 
cells. Once inside the brain, the microenvironment of this secondary organ plays a crucial 
role in cell fate decision and, whether malignant cells proliferate, in the subsequent 
formation of well-established brain metastases. 
 
3.2. Proliferation in brain microenvironment 
The microenvironment as well as organ-related factors can favour the organ-
specific pattern of spread presented by tumour cells, and either promote or supress the 
proliferation of these cells within the metastatic organ. Stephen Paget was the first one to 
postulate that the conditions that promote the formation of metastases were not purely 
anatomical, and hypothesized that the propensity that malignant cells have to spread to 
specific sites was dependent upon two factors: the cancer cell (‘seed’) and the receiving 
organ environment (‘soil’) (Paget 1889). Later, an alternative theory by James Ewing 
arose, postulating that mechanical forces and circulatory patterns between the primary 
tumour and the specific secondary organ played the main role in the metastatic process 
(Ewing 1928). More recently, a newer hypothesis postulates that cancer cells have the 
ability to bring their own soil from the primary site – stromal components, such as 
activated fibroblasts – to the secondary organ (Duda et al. 2010). Despite the existence of 
several theories to justify the preference that tumour cells have for certain organs, there 
are still numerous cellular and molecular aspects of the metastatic process that remain a 
mystery to unravel. 
Once inside the brain, BCCs have three possible fates: dormancy, proliferation, or 
cell death. Cancer cells that enter in a state of dormancy (also designated as quiescence) 
do not form metastases, not because they undergo apoptosis, but simply because they are 
in a nonproliferating state (Heyn et al. 2006, Sosa et al. 2014). The dormant malignant 
cells can reside in the brain for decades until their activation to initiate cancer growth 
(Chambers et al. 2002, Barkan et al. 2008). The BCCs that adopt this nonproliferating 
state acquire a perivascular localization, solitary or organized in tiny clusters, through the 
establishment of a persistent association with the vasculature by using GJ protein Cx43 
(Kienast et al. 2010, Ghajar et al. 2013, Stoletov et al. 2013). This intimate connection 
with the abluminal side of ECs of cerebral capillaries not only allows the survival of 
dormant malignant cells, but also potentiates the successful proliferation and formation 
of metastases. Thus, the perivascular localization of cancer cells may probably be a 
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tumour adaption to acquire an optimal oxygen supply and access to nutrients. The 
induction of the dormant-to-proliferative metastatic switch is strongly influenced by 
interactions between the tumour cell and the ECM, and is regulated by signalling 
pathways, including Src-dependent integrin β1 signalling cascade (Chambers et al. 2002, 
Barkan et al. 2008). The transition to a proliferative state is associated with drastic 
reorganization of the cytoskeleton and activation of myosin light chain kinase. Thus, both 
ECs and ECM may play an active role in regulating tumour dormancy. In addition to 
dormancy, proliferation and cell death are also cell fates regulated by the balance of 
signalling pathways, such as PI3K/Akt/mTOR, which inhibits programmed cell death 
through a prosurvival mechanism (Guo et al. 2015, Molnár et al. 2016). Similarly to 
dormancy, BCCs can also use Cx43 and L1 cell adhesion molecule, which is expressed 
by metastatic cells for spreading along brain capillaries and for metastasis outgrowth, to 
initiate brain metastatic lesion formation in association with vasculature (Stoletov et al. 
2013, Valiente et al. 2014). Extravasated cancer cells remain in contact with BMVECs 
not only because vascular BM can provide the support for metastasis formation prior to 
the formation of tumour vasculature, called as vessel co-option, but also because BBB 
protects tumour cells against antitumour immunity and chemotherapeutics drugs 
(Carbonell et al. 2009, Alkins et al. 2013, Yoshida et al. 2014). Vascular co-option is a 
mechanism through which the tumour mass obtains an adequate blood supply by 
leveraging preexisting vessels for growth and dissemination in the brain, independently 
of sprouting angiogenesis that consists in expansion and remodelling of existing vessels 
(Leenders et al. 2002, Bugyik et al. 2011). Indeed, the perivascular localization of BCCs 
allows the interaction with the vascular BM, an active substrate for BCC growth, thus 
supporting the formation of metastasis prior to the development of the new tumour vessels 
(Carbonell et al. 2009). For this reason, the ‘soil’ for cancer cells in the CNS has been 
suggested to be vascular rather than neuronal. This assumption is supported by the 
extensive brain microvasculature, estimated as 12-20 m2 in the human brain, and by the 
fact that the brain receives around 20% of cardiac output, despite representing only 2% 
of body mass (Zlokovic 2011, Abbott 2013). Vascular co-option and angiogenesis have 
distinct contributions during the initiation of micrometastases, depending not only on the 
cell numbers in the microtumour, but also on blood supply of local microenvironment 
(Zhao et al. 2011). In addition to vascular co-option and angiogenesis, aggressive BCCs 
also have the ability to differentiate into endothelial-like cells, and form vessel-like 
structures that provide blood supply from the vasculature to hypoxic regions of the tumour 
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(Qiao et al. 2015, Wagenblast et al. 2015). This capability of cancer cells to develop a 
vascular phenotype is termed as vascular mimicry. Although in the brain this 
phenomenon has only been described in glioblastoma (a malignant primary brain tumour) 
(El Hallani et al. 2010), malignant cell-mediated vascular mimicry plays a vital role in 
the tumour development independent of angiogenesis. Thus, the anti-angiogenic therapies 
can be ineffective to treat metastatic brain tumours since cancer cells can adopt survival 
strategies independent of angiogenesis. 
The formation of brain metastasis depends on the reception of multiple inputs 
from microenvironment by tumour cells, sustaining their survival, migration, and 
proliferation. The brain possesses a unique microenvironment composed by neurons, 
astrocytes, microglia, and pericytes (Cardoso et al. 2010, Sá-Pereira et al. 2012), as 
depicted in Figure 5. Along with BMVECs, all these cells are in dynamic contact, and 
together form the neurovascular unit. Thus, once inside the brain, proliferating tumour 
cells must interact with resident cells in order to survive and grow in this secondary organ. 
Thence, understanding the functional involvement of surrounding cells as well as brain-
related factors can be crucial to realize how they contribute to brain metastasis formation. 
Neurons transmit information through neurotransmitters, wherein glutamate and 
γ-aminobutyric acid (GABA) are two of the most available neurotransmitters in the brain 
responsible for excitatory and inhibitory signalling, respectively (Schousboe et al. 2013). 
Curiously, BCCs metastasizing into the brain can upregulate the GABAA receptor and 
GABA transporters, which leads to an increased uptake and metabolization of 
extracellular GABA as a biosynthetic energy source (Schousboe et al. 2013, Neman et al. 
2014). In addition, carcinoma cells can use glutamate decarboxylase to synthetize GABA 
from glutamate, being this latter neurotransmitter an additional metabolic source for 
metastatic cancer cells. The acquisition of brain-like properties by BCCs can be a 
malignant adaptation for these cells to survive, invade and grow into the brain, and thus 
for brain colonization.  
Neurons can establish interactions with glial cells and BMVECs. During brain 
metastasization, cancer cells induce, directly or indirectly, damage in surrounding 
neurons (Budde et al. 2012). This damage can be caused by hypoxia, vascular co-option, 
and excitotoxicity, as a result of cancer proliferation. In addition, malignant cells express 
calcium-binding protein S100A4, which has a dual role. On one hand, S100A4 promotes 
the formation of brain metastasis since this metastasis-associated protein participates in a 
wide range of biological functions, including regulation of angiogenesis, invasion, and 
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cell survival (Boye and Maelandsmo 2010, Dmytriyeva et al. 2012). On the other hand, 
S100A4 protects neurons from oxidative stress-related death via IL-10R/JAK/STAT3 
pathway, a signalling pathway that upregulates antioxidant enzymes and neuroprotective 
genes in neural cells (Dziennis and Alkayed 2008, Dmytriyeva et al. 2012, Bourgeais et 
al. 2013). Astrocytes are a type of glial cells that interacts with neurons and has an 
important role in metastasization. Among the proteins produced by astrocytes are MMPs, 
Fig. 5 Schematic representation of key interactions between breast cancer cell (BCC) and 
neuron, astrocyte, microglia, and pericyte in brain microenvironment. During the 
formation of brain metastasis, BCC has a dual role on neuron: either induces damage or 
produces proteins that protect this cell. In addition, cancer cell has the ability to uptake 
and metabolize γ-aminobutyric acid (GABA), and use this neurotransmitter as a 
biosynthetic energy source. Astrocyte interacts with BCC through the production of 
proteins, such as matrix metalloproteinases (MMPs), growth factors and chemokines that 
promote metastasis formation. In turn, BCC secretes active factors in order to maintain 
the astrocytic activity and proteins expression. In addition, astrocyte protects the BCC 
from apoptosis induced by chemotherapeutic drugs. Microglia has a dual role in BCC, 
causing cytotoxic effect and producing growth factors, chemokines, and cytokines that 
are involved in proliferation, angiogenesis, and immune response. In response to the 
cytotoxic effect of microglia, BCC is able to reduce the number of activated cytotoxic 
microglia through the secretion of neurotrophin-3. Finally, pericyte has an indirect 
influence in metastasization, since this cell type is involved in angiogenesis. 
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growth factors, and chemokines (Kim et al. 2013, Wang et al. 2013). In turn, tumour cells 
release active factors, such as interleukin-1β, -6, and -8, to stimulate the production of 
astrocytic proteins (Xing et al. 2013, Yoshida et al. 2014). In addition to the protection of 
neurons against toxic substances, reactive astrocytes accumulate around metastatic cells 
throughout their development into macroscopic metastases (also designated as 
macrometastases), providing protection to BCCs from apoptosis induced by 
chemotherapeutic drugs (Lorger and Felding-Habermann 2010, Yoshida et al. 2014). 
Thence, an effective mechanism to prevent tumour outgrowth and metastasis can pass 
through blocking the release of substrates by BCCs or surrounding cells into the 
microenvironment.  
Microglia are a cellular type also present in brain microenvironment that have a 
dual function in formation of brain metastasis. In fact, these neuroglial cells have been 
shown to exert cytotoxic effects towards cancer cells via production of nitric oxide, a 
major diffusible mediator that induces death in adjacent cells when in high levels 
(Brantley et al. 2010). In return to microglia-induced nitric oxide production, BCCs are 
able to reduce the number of activated microglia releasing neurotrophin-3, a neurotrophic 
factor for neural survival, development, and plasticity (Louie et al. 2013). On the other 
hand, the interaction between microglia and BCCs upregulates proteins, including 
CXCR4, platelet-derived growth factor A (PDGF-A), VEGFs, and cytokines that are 
involved in regulation of proliferation, angiogenesis, and immune response (Pukrop et al. 
2010). Thus, activated microglia are attracted and migrate to brain injury, where the 
accumulation of these glial cells facilitate the establishment of synapse-like contact with 
metastatic cancer cells (Fitzgerald et al. 2008, Pukrop et al. 2010). Despite the fact that 
the role of microglia during the metastatic process is not completely known yet, activated 
microglia serve as vehicles and guidance cells for the malignant ones into the brain. 
Regarding pericytes, these non-ECs intermittently located around the vessel walls 
are closely related with ECs and enclosed within the BM of microvessels (Sá-Pereira et 
al. 2012). Among their multiple functions are the maintenance of BBB properties and the 
regulation of vascular development, stabilization and remodelling. During the formation 
of new blood vessels, sprouting vascular ECs express PDGF-B to recruit pericytes that 
express the corresponding surface receptor, PDGF receptor beta (PDGFR-β) (Bergers and 
Song 2005, Kienast et al. 2010). Thus, this paracrine signalling between the two cell types 
mediates pericyte recruitment to the vessel wall, being crucial to the proper integrity of 
structural vasculature. Although knowledge about the involvement of pericytes in brain 
Brain metastasization of breast cancer 
36 
 
metastases is scarce, these cells are also recruited to sparks ECs of new vessels during 
tumour angiogenesis (Birbrair et al. 2014). Therefore, pericytes may not interact directly 
with cancer cells, but they promote proliferation and metastasization through 
angiogenesis. Thus, inhibition of these neurovascular unit cells, induced by nanoparticles 
or other antiangiogenic agents, may be an effective therapeutic strategy to prevent the 
angiogenesis-dependent formation of well-established metastasis (Guan et al. 2014).  
The crosstalk between malignant cells and resident cells occurs when the first cells 
arrive in the brain, resulting in the activation of a cascade of different pathways in both 
tumour and host cells. Furthermore, tumour cells are able to grow in this secondary organ 
through the gain of ability to exploit the brain endogenous substrates secreted by 
neighbouring parenchyma cells. The intensive and permanent communication between 
tumour and host cells promotes the formation of well-established metastasis. 
 
3.3. Mesenchymal-epithelial transition and brain colonization 
Considerable research effort has been concentrated in understanding the initial 
steps of the metastatic process, whereas the mechanisms involved in formation of 
secondary tumours in distal organs are much less understood. This final step of the 
invasion-metastasis cascade may take years, or even decades, to occur following 
diagnosis and treatment of the primary tumour, mainly because of dormancy of cancer 
cells (Witzel et al. 2016). Although the brain microenvironment plays an important role 
during metastasization by inducing the dormant-to-proliferative metastatic switch, the 
reacquisition of epithelial phenotype by malignant cells may be the potential mechanism 
that contributes to the establishment of macrometastases in the brain.   
A phenotypic reverse process to the initial EMT that occurs at the primary tumour 
site, the MET, is an under-investigated mechanism that contributes substantially to the 
successful colonization of cancer cells at the secondary site (Gunasinghe et al. 2012). 
During the MET, the reepithelialization of BCCs occurs, i.e., cancer cells reexpress 
epithelial proteins, such as E-cadherin and pan cytokeratin, and downregulate the 
expression of mesenchymal proteins, including N-cadherin, vimentin, and Twist (Chao 
et al. 2010, Yoshida et al. 2014). This phenotypic change promotes the adaption, 
integration, and survival of metastatic cancer cells at the microenvironment of secondary 
organ (Chao et al. 2010). Although the induction and regulation of MET in malignant 
cells are not fully understood, the neurotrophin-3, secreted by tumour cells to reduce the 
cytotoxic effect of microglia, also plays a key role in the reversion of BCCs to an 
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epithelial-like state (Louie et al. 2013). In fact, neurotrophin-3 action reduces the 
migratory ability of carcinoma cells, and consequently facilitates the tumour growth in 
the brain. Thus, the brain microenvironment, direct or indirectly, appears to play an 
important role in promoting the survival of metastatic cancer cells via establishment of 
cell-cell interactions. Curiously, malignant cells can also undergo a partial MET, 
upregulating epithelial markers, despite maintaining the expression of mesenchymal 
markers (Chao et al. 2012). The partial MET allows BCCs not only to colonize the brain 
establishing connections with neighbouring malignant cells via E-cadherin, but also to 
undergo a second EMT for further dissemination into other cerebral areas. In addition to 
reexpression of E-cadherin, the expression of GJ proteins Cx26 and Cx43 is increased in 
brain metastases formed by BCCs, suggesting that the GJs could contribute to MET (Chao 
et al. 2012). Concerning to signalling, MET is a process dependent on balance between 
pathways that promote this transition, such as PI3K/Akt signalling, and pathways 
involved in prevention of MET, including TGF-β signalling (Xue et al. 2012). Therefore, 
inhibition of MET may contribute to prevent the growth of secondary tumours in BC 
patients with metastatic diseases.  
There are still major gaps in our understanding of the mechanisms behind the 
process of brain colonization by carcinoma cells, namely on whether the formation of 
macrometastasis is the result of: 1) successive cell division and genetic instability of 
cancer cells; or 2) the continued entry of malignant cells into vascular areas where the 
BBB is compromised, promoted or not by tumour cells that are already within the brain. 
The first hypothesis is the most likely to occur since in vivo studies have demonstrated, 
through a convenient label detection, that proliferating cells rapidly generate new 
progenitors through cell divisions, thus possessing stem cell-like characteristics 
(Kusumbe and Bapat 2009, Stoletov et al. 2013). In addition, the metastatic brain tumour 
is associated to an alteration in transcription factor genes involved in cellular mechanisms, 
such as cell growth, differentiation, and cellular reprogramming via MET (Jeevan et al. 
2016). Furthermore, astrocytes present in brain microenvironment also contribute to 
tumour cells growth, promoting not only the entry in S-phase of cell cycle, the phase 
responsible for the DNA replication, but also the self-renewal of BCCs, a process that 
gives rise to indefinitely more cells of the same cell type (Xing et al. 2013, Jeevan et al. 
2016). Thus, MET together with the cerebral microenvironment appear to play a critical 
role in the development of macrometastasis in the brain. 
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As during BC growth, invasion, intravasation, and extravasation, angiogenesis 
also plays a pivotal role during secondary tumour growth. Once malignant cells 
extravasate into the brain, these cells usually remain in close contact with vascular ECs, 
and have the ability to obtain blood supply only through vascular co-option (Lorger and 
Felding-Habermann 2010). When the secondary tumour mass grows and reaches a 
macroscopic size, vessel co-option is followed by vessel regression and stimulation of 
angiogenesis, which shall provide the nutrients and oxygen to the mass of metastatic 
tumour cells (Holash et al. 1999). The enhancement of angiogenesis is induced by the 
significantly increased production of VEGF-A and angiopoietin-2 by BCCs (Kim et al. 
2004, Avraham et al. 2014). In fact, brain lesions present lower vascular permeability, 
but more angiogenesis compared to primary tumours (Monsky et al. 2002). Thus, the 
mechanisms behind the formation of new blood vessels and/or recruitment of preexisting 
vessels appear to be strongly dependent on tumour cell origin as well as on the brain 
microenvironment. Although angiogenesis is believed to be crucial for the growth of 
brain metastatic tumours, carcinoma cells can survive and proliferate without the 
formation of new vessels. In some cases, BCCs proliferate within small blood vessels and 
grow intravascularly (Lu et al. 2007). Their continuous growth leads to disruption of the 
BBB, and ultimately to thrombosis-like infarction of the brain parenchyma. In addition, 
the malignant cells localised along the vessels whose barrier property is compromised 
migrate to distant sites to maintain protected by an intact BBB (Lu et al. 2007). Curiously, 
tumour cells adhere directly to the BM of the capillary, replacing the astrocytes from the 
basal surface, but remaining the original structure of incorporated vessels. Hence, the 
carcinoma cells have the ability to adapt to the brain microenvironment, distributing in 
ideal sites where they can receive nutrients and oxygen to promote their proliferation, and 
hence form brain metastasis.   
The formation of robust macrometastasis represents the endpoint of the multistep 
metastatic process. Only a small minority of cancer cells, the most metastatic ones, have 
the ability to overcome all the obstacles that normally prevent the formation of secondary 
tumours. Therefore, a successful metastatic tumour cell is able to pass through the growth 
in situ, invasion of mammary duct, migration toward a blood vessel wall, intravasation 
into the bloodstream, survival during the course from the primary to secondary site, 
extravasation across vascular endothelium barrier, establishment of interactions with 
microenvironment cells, and finally formation of metastasis. During all the invasive-
metastatic cascade, reciprocal interactions between tumour and host cells play a pivotal 
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role, allowing the adaptation of malignant one to the different microenvironment in which 
the cell passes, and thus promoting the metastasization of the ‘target organ’. So, despite 
the already developed studies allow to understand and unravel, even partially, the 
mechanisms of the metastatic steps that culminate in well-establishment of metastasis, 
more studies are needed to develop novel therapeutic approaches able to prevent the 
formation of these growths at distant organs. 
 
 
4. Conclusion 
Over the past decades, a substantial improvement in the diagnosis and treatment 
of BC patients, including those who evolve to a metastatic stage, has been achieved. One 
exception respects to the patients with brain metastasis for whom there is still no efficient 
treatment. Since brain metastasization is a major clinical problem and a leading cause of 
death from cancer, it is pivotal a better knowledge of the pathways that orchestrate the 
invasion-metastasis cascade. However, compared to other ‘target organs’ of BCCs, such 
as the bone, the mechanisms responsible for CNS metastasis formation remain poorly 
understood and substantially less frequently investigated. In addition, the existence of the 
BBB, the capacity of cancer cells to migrate to sites where the endothelium barrier 
remains intact, and the protection provided to malignant cells by host cells render difficult 
the development of an optimal strategy for the treatment of patients with brain metastasis. 
One important strategy may involve the prediction of occurrence of brain metastasization 
through the discovery of new biomarkers and genetic signatures, and/or the 
comprehension of cellular behaviour of cancer cells that are in circulation or even in 
primary tumour site. This way, in addition to overcoming the BBB for the transport of 
therapeutic agents into the brain, this life-threat outcome for BC patients might become 
early detected and effectively prevented. Moreover, understanding of the contribution of 
interactions between metastatic BCCs and host cells, especially ECs, to successful brain 
colonization may also provide other therapeutic approach to prevent or decrease the 
formation of brain metastasis. Since the roles played by host cells during the 
establishment of metastasis are rapidly beginning to be appreciated, this strategy can be 
crucial to develop specific therapies to prevent the brain metastasis formation. Therefore, 
although enormous challenges remain, it is anticipated that the continuous research in 
brain metastasization area will culminate into novel clinical approaches. 
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5. Aims 
The exact mechanisms, including the time at which they occur and their 
intervenients, involved in brain metastasization of BC still need to be elucidated, mainly 
those that occur once malignant cells cross the BBB. Therefore, with this project we 
aimed to: (1) establish the temporal profile of BCCs metastasization to the brain and 
characterize the metastasizing cells phenotype, (2) investigate the BBB properties and 
vascular events along the process of BC metastasization to the brain, and (3) assess 
signalling mechanisms involved in attraction of malignant cells into the brain and 
proliferation in the nervous tissue. To this end, we used female mice inoculated with 4T1 
BCCs sacrificed at 5 hours, 3 days, 7 days or 10 days and mice injected with vehicle 
(control) sacrificed at 5 hours to profile the alterations of BBB and brain parenchyma 
along the metastatic progress, to establish the temporal sequence of these alterations, and 
to relate them with the appearance of brain metastases. Thus, we will contribute to clarify 
the time-course and cellular and molecular players behind the establishment of brain 
metastasis of BC. 
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Abstract  
Brain metastasization of breast cancer is a multistep process dependent on the 
attraction of cancer cells to the brain endothelium and their posterior transendothelial 
migration by still unclear pathways. This study was designed to characterize the process 
of brain metastasization in terms of the phenotype of malignant cells, the signaling 
molecules involved, and their relationship with the blood-brain barrier (BBB) disruption. 
Therefore, we outlined to: i) establish the temporal profile of breast cancer cells 
metastasization to the brain and characterize the metastasizing cells phenotype, ii) 
investigate the vascular events and BBB properties along the process of BC 
metastasization to the brain, and iii) assess signalling mechanisms involved in attraction 
of malignant cells into the brain and proliferation in the nervous tissue. We examined 
cerebella, cranial hippocampi, and striata of female mice inoculated with 4T1 breast 
cancer cells along the process of brain metastasization (5 hours, 3 days, 7 days, and 10 
days) and of female mice injected with vehicle (control; sacrificed at 5 hours) by 
conventional haematoxylin and eosin staining, and by immunohistochemical and 
immunofluorescence analysis. Brain metastasization resulted in the occurrence of well-
established metastasis along time, in entrance of malignant cells as mesenchymal cells 
into the brain and then the acquisition of epithelial markers by these cells, as well as the 
decrease of claudin-5 expression by brain microvascular endothelial cells, and the 
entrance of thrombin in brain parenchyma. In addition, hypervascularization in cranial 
hippocampus appeared to be associated to brain colonization. Brain metastasization also 
resulted in the increase of platelet-derived growth factor B expression by tumour cells. 
The occurrence of cysteine-X amino acid-cysteine receptor 4 (CXCR4)-positive cells 
increased in early stages of the process of brain metastasization, and then the number 
stabilized in later stages of this process. Taken together, these results highlight the 
contribution of BBB disruption, brain parenchyma alterations, signalling molecules, and 
phenotypic transition of tumour cells along the process of brain metastasization of breast 
cancer. 
 
Keywords: Blood-brain barrier disruption; breast cancer brain metastasis; extravasation; 
mesenchymal-epithelial transition; microvasculature. 
 
 
 
Capturing changes in the blood-brain barrier and brain parenchyma during  
brain metastasization of breast cancer 
60 
 
Resumo  
A metastização cerebral do cancro da mama é um processo com múltiplos passos 
dependente da atracão das células cancerígenas para o endotélio cerebral e da sua 
posterior migração através de vias ainda pouco conhecidas. Este estudo foi desenhado 
para caracterizar o processo de metastização em termo de fenótipo das células malignas, 
das moléculas sinalizadoras envolvidas e a sua relação com a disrupção da barreira 
hematoencefálica (BHE). Por este motivo, nós delineámos: i) estabelecer o perfil 
temporal da metastização por parte das células cancerígenas da mama para o encéfalo e 
caracterizar o fenótipo das células metastáticas, ii) investigar as alterações vasculares e 
as propriedades da BHE ao longo do processo de metastização do cancro da mama para 
o encéfalo, e iii) aceder aos mecanismos de sinalização envolvidos na atração de células 
malignas para o encéfalo e na proliferação no tecido nervoso. Nós examinámos cerebelos, 
hipocampos craniais e estriados de ratinhos fêmea inoculados com células cancerígenas 
da mama 4T1 ao longo do processo de metastização cerebral (5 horas, 3 dias, 7 dias e 10 
dias) e de ratinhos fêmea injetados com veículo (controlo; sacrificados às 5 horas) através 
da coloração convencional de hematoxilina e eosina e através de análise  
imuno-histoquímica e imuno-fluorescente. A metastização do encéfalo resultou no 
aparecimento de metástases bem estabelecidas ao longo do tempo, na entrada de células 
malignas expressando o seu fenótipo mesenquimal para dentro encéfalo e posterior 
aquisição de marcados epiteliais, assim como na diminuição da expressão de claudina-5 
nas junções das células endoteliais microvasculares cerebrais, e na entrada de trombina 
no parênquima encefálico. Para além disso, o aumento da vascularização no hipocampo 
cranial aparentou estar associado à colonização desta região pelas células cancerígenas 
da mama. A metastização do encéfalo também resultou no aumento da expressão do fator 
de crescimento B derivado das plaquetas pelas células tumorais. O número de células 
positivas para o recetor CXCR4 aumentou nos estadios iniciais do processo de 
metastização do encéfalo e, em estadios mais avançados deste processo, esse número 
estabilizou. Assim, estes resultados realçam a contribuição da disrupção da BHE, das 
alterações no parênquima encefálico, das moléculas sinalizadoras e da transição 
fenotípica das células tumorais ao longo do processo de metastização do cancro da mama 
para o encéfalo. 
 
Palavras-chave: Disrupção da barreira hematoencefálica; extravasação; metástases 
cerebrais do cancro da mama; micro-vasculatura; transição mesenquimal-epitelial. 
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1. Introduction 
Breast cancer (BC) represents the second most frequent cause of central nervous 
system (CNS) metastases, after lung cancer, with these secondary tumours occurring in 
12-31% of patients (Vuong et al. 2011, Saha et al. 2013). Brain metastasis is commonly 
associated with poor prognosis and diminished quality of life, being normally a 
catastrophic life-threat outcome for patients (Cruz-Muñoz and Kerbel 2011, Jaboin et al. 
2013). Unfortunately, there are no targeted therapies specific for this secondary tumour 
formation (Steeg et al. 2011), and the cellular and molecular events underlying their 
establishment and progression are poorly understood. However, it is known that the 
metastatic cascade comprises several steps, such as the epithelial-mesenchymal transition 
(EMT) in mammary duct, entrance of cancer cells into bloodstream (intravasation), arrest 
in brain capillaries, the extravasation into the ‘target organ’, and the mesenchymal-
epithelial transition (MET) that together contribute for a successful colonization of the 
brain by cancer cells (Wyckoff et al. 2000, Stoletov et al. 2010, Gunasinghe et al. 2012, 
Videira et al. 2014). The arrival of viable BC cells (BCCs) to the brain can result from a 
trapping in small vessels driven by organ-derived chemoattractants that play an important 
role in the homing of carcinoma cells into the brain (Hujanen and Terranova 1985, Lee et 
al. 2004, Salmaggi et al. 2014). The unique properties of the brain microvasculature, 
which forms the blood-brain barrier (BBB), selectively regulate the entrance of molecules 
and cells into the brain parenchyma through elaborate junctional complexes, including 
tight junctions (TJs) and adherens junctions (Cardoso et al. 2010). Despite the BBB 
restricted permeability, the most metastatic cells are able to extravasate into this 
privileged organ regarding the appearance of metastases. The extravasation of BCCs 
across the BBB involves rolling, firm adhesion of malignant cells to the brain 
microvascular endothelial cells (BMVECs), followed by transendothelial migration 
(TEM) via paracellular route (Lorger and Felding-Habermann 2010, Stoletov et al. 2010). 
During paracellular migration, the interaction between metastatic cells and BMVECs 
induces the opening of the junctions to allow the squeeze of cancer cells between two 
ECs, and thus leads to BBB disruption (Fan et al. 2011, Fan and Fu 2016). Once inside 
the brain, the colonization of this secondary organ by BCCs requires not only a 
phenotypic transition whereby malignant cells reacquire epithelial characteristics, but 
also angiogenesis to allow an optimal oxygen supply and access to nutrients, favouring 
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the formation of well-established brain metastasis (Zhao et al. 2011, Gunasinghe et al. 
2012).  
In this study, we wanted to understand the cellular and molecular events involved 
in BBB and brain parenchyma alterations that are prevalent during the brain 
metastasization. The results presented here reveal the time-course and interdependence 
of BBB breach, phenotypic alterations of malignant cells, and signalling events along the 
attraction to the BMVECs and brain metastases formation. Moreover, by establishing the 
temporal sequence of events occurring in brain metastasization and identifying the early 
ones, this study contributes to an in-depth understanding of the malignant behaviour and 
points to potential therapeutic targets for modulation in order to prevent the extravasation 
and brain colonization processes, essential to developed novel strategies to improve the 
life expectancy of BC patients. 
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2. Materials and methods 
2.1. Cell culture and animals 
Murine mammary carcinoma 4T1 cells, an aggressive metastatic triple-negative 
BCC line, were purchased from ATCC (Middlesex, UK), and maintained in RPMI 1640 
medium (PAN Biotech, Aidenbach, Germany) supplemented with Ultraglutamine I 
(Lonza, Basel, Switzerland) and 5% heat-inactivated fetal bovine serum (PAN Biotech) 
in a 5% CO2 atmosphere at 37 ºC. Female BALB/c mice at the age of 7-8 weeks were 
purchased from Charles River Laboratories (Wilmington, MA, USA), and were housed 
and bred in the animal facility of the Biological Research Centre of the Hungarian 
Academy of Sciences, Hungary. The xenographs of metastatic breast cancer (n=4) were 
developed by inoculating, under isoflurane anaesthesia, 1 х 106 4T1 cells in the right 
common carotid artery in a total volume of 200 μL of Ringer-HEPES, whereas control 
mice (n=2) were inoculated with vehicle. At 5 hours, 3, 7, or 10 days post-tumour cell 
inoculation and at 5 hours post-vehicle injection, brain tissue was harvested after 
perfusing deeply anesthetized animals with 50 mL of phosphate-buffered saline (PBS), 
followed by 25 mL of 4% paraformaldehyde in PBS. Brains were post-fixed overnight in 
4% paraformaldehyde in PBS at 4 ºC and kept in PBS. 
All procedures were conducted according to the recommendations of the 
Declaration of Helsinki and Tokyo, and were performed according to the EU Directive 
2010/63/EU on the protection of animals used for experimental and other scientific 
purposes. The protocol was reviewed and approved by the Regional Animal Health and 
Food Control Station of Csongrád County (licence number: VI-I-001/2980-4/2012) of the 
Hungarian Academy of Sciences. Fixed brain samples were shipped to the Faculty of 
Pharmacy, University of Lisbon, Portugal, where the microscopic analysis was 
performed. 
 
2.2. Histology 
Brain processing, paraffin embedded, and sectioning were performed at the 
Histology and Comparative Pathology Laboratory at Instituto de Medicina Molecular, 
headed by Doctor Tânia Carvalho. Mouse brains were serially cut into 4-μm-thick 
sections to performed the stainings and labellings described below. To establish the brain 
regions to be analysed, a preliminary set of experiments was performed in which the 
brains were coronally cut in five regions according to the following bregma coordinates: 
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medulla, -8.24 mm; cerebellum, -6.12 mm; caudal hippocampus, -3.52 mm; cranial 
hippocampus, -1.82 mm; and striatum, 0.5 mm. Analysis of the percentage of metastases 
formation by staining with haematoxylin and eosin (H&E), as described below, showed 
that cranial hippocampus and striatum were two brain regions with high percentage of 
brain metastases at later stages, that cerebellum is the brain region that presents secondary 
tumours only 10 days post-tumour cell inoculation, and that the medulla is the only brain 
region that does not present any metastasis along time (Table 1). Based on these results, 
the cerebellum, cranial hippocampus, and striatum were chosen for further analysis.  
 
Table 1 Percent distribution of metastases in each brain region of mice injected with 4T1 
cells along time. 
 
2.3. Reagents and antibodies 
Xylene and Quick-D Mounting Medium were purchased from Klinipath (Duiven, 
Netherlands). Papanicolaou’s solution 1a Harris’ haematoxylin solution, Y-solution 0.5% 
alcoholic, and Triton X-100 were obtained from Merck Millipore (Darmstadt, Germany). 
Bovine serum albumin (BSA), goat serum, and Tris borate-EDTA were acquired from 
Sigma-Aldrich (St. Louis, MO, USA). Citric acid was purchased from Chem-Lab 
(Zedelgem, Belgium). 4’,6-diamidino-2-phenylindole (DAPI) and SlowFade® Diamond 
Antifade Mountant were obtained from Thermo Fisher Scientific (Waltham, MA, USA). 
All other chemicals were of analytical grade.  
Mouse monoclonal anti-claudin-5 (4C3C2), rabbit polyclonal anti-
CXCR4/CD184, rabbit polyclonal anti-N-cadherin/CDH2, mouse monoclonal anti-pan 
Cytokeratin (C-11), rabbit polyclonal anti-PDGF-B, rabbit polyclonal anti-vimentin, goat 
anti-rabbit Alexa Fluor® 555, goat anti-mouse Alexa Fluor® 647, and SuperPicture™ 
Polymer Detection Kit, DAB, broad spectrum polymer were from Thermo Fisher 
Scientific. Fluorescein-conjugated Lycopersicon esculentum (tomato) lectin was obtained 
 
Timepoint 
 
Brain region 
Medulla Cerebellum Caudal 
hippocampus 
Cranial 
hippocampus 
Striatum 
5 hours 0.0 0.0 0.0 0.0 0.0 
3 days 0.0 0.0 50.0 0.0 50.0 
7 days 0.0 0.0 29.3 28.9 41.8 
10 days 0.0 9.3 25.8 33.5 31.4 
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from Vector Laboratories (Burlingame, CA, USA). Mouse monoclonal anti-thrombin (F-
1) was acquired from Santa Cruz Biotechnology (Burlingame, TX, USA).  
 
2.4. Haematoxylin and eosin staining 
For H&E staining, the tissue was deparaffinised in xylene (10 minutes), 
rehydrated in successive ethanol solutions (100% ethanol for 20 seconds, 96% ethanol 
for 10 seconds, and 70% ethanol for 10 seconds), and in tap water (10 seconds). The 
nuclei were stained with Papanicolaou’s solution 1a Harris’ haematoxylin solution for 4 
minutes. Sections were then differentiated using a solution of 1% hydrochloric acid in 
70% ethanol (5 seconds), and bluing in 1% ammonia water (5 seconds). The cytoplasm 
was stained with eosin Y-solution 0.5% alcoholic for 10 minutes. Finally, sections were 
dehydrated, and mounted with Quick-D Mounting Medium.  
 
2.5. Immunofluorescence and immunohistochemistry 
Tissue sections were labelled for claudin-5, cysteine-X amino acid-cysteine 
receptor 4 (CXCR4), pan Cytokeratin, thrombin, tomato lectin, and vimentin by 
immunofluorescence (IF), or stained for neuronal cadherin (N-cadherin), and platelet-
derived growth factor B (PDGF-B) by immunohistochemistry (IHC), as described below.  
For IF labelling, tissue sections were deparaffinised in xylene (20 minutes), and 
rehydrated through successive immersion in 100% ethanol (20 minutes), 96% ethanol (10 
minutes), 70% ethanol (10 minutes), and finally tap water (10 minutes). A 3% hydrogen 
peroxide solution was used to inhibit endogenous peroxidase activity, for 30 minutes. 
Heat-mediated antigen retrieval was performed with 10 mM citrate buffer pH 6.0 during 
15 minutes for sections to be labelled for claudin-5, CXCR4, pan Cytokeratin, tomato 
lectin, and vimentin, or with 10 mM Tris-borate EDTA buffer pH 9.0 during 10 minutes 
for sections to be labelled for thrombin. A permeabilization step was performed with 0.5% 
Triton X-100 for 15 minutes (with the exception of sections for thrombin), and tissue 
sections were blocked with 3% BSA during 60 minutes. The primary antibodies were 
diluted in 3% BSA, 0.5% Triton X-100 solution, and sections were incubated overnight 
at 4 ºC. Then, the incubation with the respective fluorescent-labelled secondary antibody 
(anti-rabbit Alexa Fluor® 555, or anti-mouse Alexa Fluor® 647) diluted in 3% BSA were 
performed during 60 minutes at room temperature, as summarized in Table 2. After the 
antigen retrieval treatment, washes were performed using PBS three times for 10 minutes 
between all the steps. Negative controls with omission of primary antibodies were 
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performed to exclude nonspecific binding or cross reactivity. Nuclei were labelled with 
DAPI diluted 1:1000 in PBS for 2 minutes, followed by slides mounting with SlowFade® 
Diamond Antifade Mountant.  
 
 
Table 2 Summary of the antibodies and experimental conditions used for 
immunofluorescence and immunohistochemical analysis. 
Technique Marker Primary antibody Dilution Secondary antibody Dilution 
IF 
Claudin-5 Thermo Fisher Scientific, 
#35-2500, Mouse Mc 
1:500 Alexa Fluor® 647 
Thermo Fisher Scientific,  
#A-21235 
Goat anti-mouse 
1:500 
CXCR4 Thermo Fisher Scientific, 
#PA3-305, Rabbit Pc 
1:100  Alexa Fluor® 555 
Thermo Fisher Scientific,  
#A-21428 
Goat anti-rabbit 
1:500 
pan CK Thermo Fisher Scientific, 
#MA5-12231, Mouse Mc 
1:100  Alexa Fluor® 647 
Thermo Fisher Scientific,  
#A-21235 
Goat anti-mouse 
1:500 
Tomato 
lectin 
Vector Laboratories,  
#FL-1171 
1:400  NA NA 
Thrombin Santa Cruz 
Biotechnology,  
#sc-271449, Mouse Mc 
1:200  Alexa Fluor® 647 
Thermo Fisher Scientific,  
#A-21235 
Goat anti-mouse 
1:500 
Vimentin Thermo Fisher Scientific, 
#PA5-27231, Rabbit Pc 
1:100  Alexa Fluor® 555 
Thermo Fisher Scientific, 
#A-21428 
Goat anti-rabbit 
1:500 
IHC 
N-cadherin Thermo Fisher Scientific, 
#PA5-19486, Rabbit Pc 
1:100 HRP from 
SuperPictureTM Polymer 
Detection Kit 
Thermo Fisher Scientific, 
#87-9663 
 
NA 
PDGF-B Thermo Fisher Scientific, 
#PA1-27394, Rabbit Pc 
1:75 HRP from 
SuperPictureTM Polymer 
Detection Kit 
Thermo Fisher Scientific, 
#87-9663 
 
NA 
CK, cytokeratin; CXCR4, cysteine-X amino acid-cysteine receptor 4; HRP, horseradish 
peroxidase; IF, immunofluorescence; IHC, immunohistochemistry; Mc, monoclonal; NA, 
not applicable; N-cadherin, neuronal cadherin; Pc, polyclonal; PDGF-B, platelet-derived 
growth factor B. 
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For IHC staining, tissue sections were deparaffinised in xylene (20 minutes), and 
rehydrated through successive immersion in 100% ethanol (20 minutes), 96% ethanol (10 
minutes), 70% ethanol (10 minutes), 50% ethanol (10 minutes), and finally tap water (10 
minutes). A 3% hydrogen peroxide solution was used to inhibit endogenous peroxidase 
activity, for 30 minutes. Heat-mediated antigen retrieval was performed with 10 mM 
citrate buffer pH 6.0 during 15 minutes. The tissue sections stained for PDGF-B were 
blocked with a 3% BSA, 0.5% Triton X-100 solution and sections stained for N-cadherin 
were blocked in a 5% goat serum, 1% TritonX-100 solution for 60 minutes. The primary 
antibodies were both diluted in the respective blocking solutions, at concentrations 
indicated in Table 2, and sections were incubated overnight at 4 ºC. Then, the 
SuperPicture™ Polymer Detection Kit was used according to the manufacturer’s 
instructions to detect positive staining, followed by development with  
3,3’-diaminobenzidine tetrahydrochloride (DAB) for 1 minute for N-cadherin staining or 
for 2 minutes for PDGF-B staining. After the antigen retrieval treatment, washes were 
performed using PBS three times for 10 minutes between all the steps. For N-cadherin, 
washes after the incubation with primary antibody were performed with PBS, 1% Triton 
X-100 solution, also three times for 10 minutes. Negative controls with omission of 
primary antibodies were performed to exclude nonspecific binding or cross reactivity. 
Haematoxylin counterstaining was performed only for N-cadherin immunostaining. 
Finally, sections were dehydrated, and mounted with Quick-D Mounting Medium.  
 
2.6. Data analysis 
For the analysis of the metastases distribution, the brain metastases of each brain 
region (the medulla, the cerebellum, the caudal hippocampus, the cranial hippocampus, 
and the striatum) at each timepoint were counted manually by a single observer. The 
number of metastases per region was presented as percentage of the total number of 
metastases detected in the entire brain at each timepoint.  
Photographs of H&E and IHC staining were acquired on bright field microscope 
(Olympus, model BX51) with an integrated digital camera (Olympus, model DP50) and 
photographs of IF labelling were acquired on confocal microscope (Leica, model TCS 
SPE), equipped with 3 lasers (488, 532, and 635 nm). Ten fields of the cerebellum, cranial 
hippocampus, and striatum of each animal were analysed using the ImageJ 1.29x software 
(National Institutes of Health, USA), as detailed below.  
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Metastases appearance and development were analysed based on the evaluation 
of total tumour area determined by delimitation of each metastasis per field, and results 
were expressed in μm2 of tumour area. For evaluation of malignant cells entrance into the 
brain parenchyma, the number of individual vimentin-positive cells inside or near a blood 
vessel per field was measured. Moreover, the formation of brain metastasis was also 
analysed based on the evaluation of the number of vimentin-positive cells per field. To 
evaluate the phenotypic changes of tumour cells, the malignant cells were classified 
according to their phenotype in vimentin-positive/pan Cytokeratin-negative, vimentin-
positive/pan Cytokeratin-positive, and vimentin-negative/pan Cytokeratin-positive, and 
the number of cells expressing the respective phenotype per field was counted. For 
evaluation of TJ protein claudin-5 immunoreactivity in ECs, each blood vessel was 
delimited, the vascular immunoreactivity was measured, and results were expressed by 
the mean intensity of claudin-5 per μm2 of blood vessel. To evaluate the entrance of 
thrombin into the brain parenchyma, an indicator of BBB hypermeability (Janota et al. 
2015), the total number of thrombin deposits per section was measured. In addition, 
vascular parameters were analysed based on the TJ marker claudin-5. To evaluate the 
microvascular density, the area of claudin-5-positive blood vessels per field was 
measured (Brito et al. 2013), and data was expressed as total area of blood vessels per 
μm2 of brain tissue. To analyse the number of cells expressing of PDGF-B, the number of 
PDGF-B-positive cells per field was counted. Moreover, the number of cells expressing 
CXCR4 was evaluated by measuring the number of CXCR4-positive cells per field.  
 
2.7. Statistical analysis 
Results were analysed using GraphPad Prism® 5.0 (GraphPad Software, San 
Diego, CA, USA), and are expressed as mean±SEM. One-way ANOVA and the Dunnett 
post hoc test were used to compare how the parameters evolved in 4T1 and vehicle 
injected mice at each timepoint, for each brain region separately. In addition, one-way 
ANOVA and the Bonferroni post hoc test were used to evaluate how the parameters 
evolved in 4T1 injected mice groups along time for each brain region separately and to 
determine whether there were statistically significant differences between brain regions. 
P values less than 0.05 were considered statistically significant. 
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3. Results 
3.1. Brain metastases occur from 7-days onwards after inoculation 
To monitor metastases appearance and development, the tumour area was 
determined for cerebellum, cranial hippocampus and striatum of 4T1 injected mice along 
time (Fig. 1). Observation of H&E stained sections revealed that well-established 
metastasis occurred at 7 days in all three brain regions, which augmented thereafter (Fig. 
1a, b, and c). There was a ~3-fold or higher increase of the tumour area from 7 to 10 days 
in all three brain regions (Fig. 1d, e, and f). In line with the preliminary set of experiments 
(Table 1), the cerebellum was the least affected region. In fact, the cerebellum had four 
times less tumour area at 7 days compared to cranial hippocampus, even though not 
significant, and almost three times less at 10 days (P<0.01). Thus, these results show that 
the appearance of brain metastasis with larger dimensions (or macrometastases) occurs 
from 7-days onwards after the inoculation of breast tumour cells. 
 
3.2. Malignant cells undergo a mesenchymal-epithelial transition 
Having established the profile of brain metastases occurrence, we further wanted 
to identify individual tumour cells and establish if they cross the BBB in their 
mesenchymal phenotype and maintain this phenotype until brain colonization, when 
malignant cells undergo the MET. For these purposes, we analysed the time-dependent 
expression of widely used mesenchymal (N-cadherin and vimentin) and epithelial 
(tomato lectin and pan Cytokeratin) markers, alone or in combination (Fig. 2-5).  
The IHC analysis of N-cadherin showed the presence of individual N-cadherin-
positive cells already at 5 hours post-tumour cell inoculation, and that these cells were 
normally localized near blood vessels in all brain regions (Fig. 2a, b, and c). Observation 
of N-cadherin staining along time suggests an increase of the number of positive-cancer 
cells at 3 days in all brain regions compared to 5 hours. At 7 and 10 days, the BCCs that 
composed macrometastases did not express N-cadherin, whereas individual cells still 
express the mesenchymal marker, as observed in the cerebellum at 7 days (Fig. 2a). These 
results suggest that malignant cells extravasate into the brain as mesenchymal cells, and 
that once inside this secondary organ, they lose the mesenchymal characteristics as brain 
metastases are formed.  
The vimentin and tomato lectin double labelling IF analysis allowed the 
observation of cancer cells presenting a mesenchymal phenotype located inside or near a  
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Fig. 1 Tumour area occupied by breast cancer cells along the process of brain 
metastasization. Cerebellum, cranial hippocampus, and striatum sections of control mice 
and of mice at different times post-tumour cell inoculation were processed for 
haematoxylin and eosin analysis. Representative immunohistological patterns of the area 
occupied by brain metastases indicated by arrowheads in cerebellum (a), cranial 
hippocampus (b), and striatum (c). Semi-quantitative analysis of the tumour area per field 
in cerebellum (d), cranial hippocampus (e), and striatum (f). *P<0.05, ***P<0.001 vs. 
control; ###P<0.001 between indicated groups. 
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blood vessel, and the epithelial phenotype expressed in well-established metastases (Fig. 
3). In fact, analysis of vimentin expression by tumour cells of 4T1 injected mice showed 
an increase over time (Fig. 3a, b, and c). At 5 hours and 3 days, single cancer cells 
expressing vimentin were observed inside tomato lectin-labelled blood vessels, which do 
not have a larger diameter than the one of BCCs favouring the extravasation step into the  
Fig. 2 Changes in the expression of the mesenchymal marker N-cadherin by breast cancer 
cells along the process of brain metastasization. Cerebellum, cranial hippocampus, and 
striatum sections of control mice and of mice at different times post-tumour cell 
inoculation were processed for immunohistochemical analysis of N-cadherin. 
Representative immunohistological patterns of N-cadherin-positive cells indicated by 
arrowheads in cerebellum (a), cranial hippocampus (b), and striatum (c).   
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Fig. 3 Entrance of vimentin-positive breast cancer cells and establishment of tomato 
lectin-positive macrometastases along the process of brain metastasization. Cerebellum, 
cranial hippocampus, and striatum sections of control mice and of mice at different times 
post-tumour cell inoculation were processed for immunofluorescence analysis of the 
mesenchymal marker vimentin and the epithelial marker tomato lectin. Representative 
immunohistological patterns of vimentin-positive cells and tomato lectin-positive cells in 
cerebellum (a), cranial hippocampus (b), and striatum (c), where the arrowheads point to 
the individual vimentin-positive cells. Semi-quantitative analysis of the vimentin-positive 
cells per field in cerebellum (d), cranial hippocampus (e), and striatum (f). *P<0.05, 
**P<0.01, ***P<0.001 vs. control; #P<0.05, ##P<0.01 between indicated groups.  
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brain. In line with the results showing that individual N-cadherin-positive cells cross the 
BBB with a mesenchymal phenotype, the expression of vimentin by malignant cells 
confirms that BCCs entering the brain present mesenchymal characteristics. Along time, 
the vimentin continues to be expressed by tumour cells or, at least, by the majority of 
them, even when these cells were in well-established metastases. Interestingly, tomato 
lectin expression was also observed in metastases, pointing to the development of 
epithelial characteristics by malignant cells. Analysis of 4T1 injected mice showed that 
the number of vimentin-positive cells was remarkably increased from 3 to 7 days post-
tumour cell inoculation in the cerebellum (~26-fold, Fig. 3d), cranial hippocampus (~30-
fold, P<0.01, Fig. 3e), and striatum (28-fold, P<0.01, Fig. 3f). No further increase in the 
number of vimentin-positive cells with time (from 7 to 10 days) was observed in the 
cerebellum and striatum, whereas in cranial hippocampus a ~2-fold elevation (P<0.05, 
Fig. 3e) was observed in 4T1 inoculated mice. These results showing that BCCs maintain 
vimentin expression suggest the presence of some mesenchymal features in brain 
metastases. This result, taken together with the expression of epithelial marker tomato 
lectin by malignant cells, indicate that BCCs do not undergo a complete MET in the 
course of brain metastasization.  
In order to establish whether tumour cells undergo a complete or a partial MET 
during brain colonization, we further analysed another epithelial marker, pan Cytokeratin, 
by double labelling with the same mesenchymal marker, vimentin (Fig. 4, 5). At early 
stages, we observed that individual cells expressed mainly vimentin or, at least, the 
expression of vimentin was higher than the pan Cytokeratin expression (Fig. 4a, b, and 
c). The expression of pan Cytokeratin by tumour cells increased along time, becoming 
evident when these cells formed well-established metastases. Despite the epithelial 
phenotype of the malignant cells, BCCs maintain their mesenchymal characteristics, 
being the largest cellular population observed at 7 and 10 days composed by cells 
expressing both markers. Interestingly, it was observed that, in some well-established 
brain metastasis, the malignant cells that were positive only for pan Cytokeratin occupied 
the core of the metastases, whereas vimentin-positive (whether negative or positive for 
pan Cytokeratin) were positioned at the periphery of the secondary tumour. For an in-
depth analysis of the phenotypical transition, we classified the malignant cells into three 
groups, according to their phenotype: vimentin-positive/pan Cytokeratin-negative (Fig. 
5a), vimentin-positive/pan Cytokeratin-positive (Fig. 5b), and vimentin-negative/pan 
Cytokeratin-positive (Fig. 5c). The vimentin-positive/pan Cytokeratin-positive cells were 
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the most numerous cellular population, reaching ~40 cells per field in cranial 
hippocampus (Fig. 5h) and in striatum (Fig. 5k) at 10 days, whereas the vimentin-
Fig. 4 Phenotypic changes associated to mesenchymal-epithelial transition of breast 
cancer cells along the process of brain metastasization. Cerebellum, cranial hippocampus, 
and striatum sections of control mice and of mice at different times post-tumour cell 
inoculation were processed for immunofluorescence analysis of the mesenchymal marker 
vimentin and the epithelial marker pan Cytokeratin. Representative immunohistological 
patterns of vimentin and pan Cytokeratin double labelling in cerebellum (a), cranial 
hippocampus (b), and striatum (c), where the arrowheads point to individual  
vimentin-positive cancer cells in the parenchyma, and the insert shows a well-established 
metastasis presenting vimentin-negative/pan Cytokeratin-positive cells inside the 
secondary tumour and vimentin-positive/pan Cytokeratin-negative cells in the periphery 
of the metastasis. 
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positive/pan Cytokeratin-negative cells were the population with the lowest number of 
malignant cells, never exceeding 2 cells per field in any brain region (Fig. 5d, g, and j). 
The number of vimentin-positive/pan Cytokeratin-negative cells increased until 7 days 
Fig. 5 Changes in the expression of the mesenchymal marker vimentin and the epithelial 
marker pan Cytokeratin by breast cancer cells associated to mesenchymal-epithelial 
transition along the process of brain metastasization. Cerebellum, cranial hippocampus, 
and striatum sections of control mice and of mice at different times post-tumour cell 
inoculation were processed for immunofluorescence analysis of vimentin and pan 
Cytokeratin. Representative immunohistological patterns of vimentin-positive/pan 
Cytokeratin-negative (a), vimentin-positive/pan Cytokeratin-positive (b), and vimentin-
negative/pan Cytokeratin-positive (c) phenotypes. Semi-quantitative analysis of the 
number of vimentin-positive/pan Cytokeratin-negative cells per field in cerebellum (d), 
cranial hippocampus (g), and striatum (j). Semi-quantitative analysis of the  
vimentin-positive/pan Cytokeratin-positive cells per field in cerebellum (e), cranial 
hippocampus (h), and striatum (k). Semi-quantitative analysis of the  
vimentin-negative/pan Cytokeratin-positive cells per field in cerebellum (f), cranial 
hippocampus (i), and striatum (l). *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, 
##P<0.01 between indicated groups. 
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post-tumour cell inoculation in all three brain regions, tending to decrease thereafter in 
all regions (Fig. 5d, g, and j). Analysis of vimentin-positive/pan Cytokeratin-positive 
phenotype revealed that during the brain metastasization process there was an abrupt 
increase of cells expressing this phenotype in all three brain regions from 3 to 7 days (Fig. 
5e, h, and k), which was significant in cranial hippocampus (~26-fold, P<0.01, Fig. 5h) 
and striatum (~52-fold, P<0.05, Fig. 5k). The number of vimentin-positive/pan 
Cytokeratin-positive cells continued to increase ~2-fold from 7 to 10 days in all brain 
regions, varying significantly in striatum (P<0.05, Fig. 5k). This increase was also 
accompanied by an augment of vimentin-negative/pan Cytokeratin-positive cells in all 
brain regions (Fig. 5f, i, and l), which was significant in cranial hippocampus (~4-fold 7 
days vs. 10 days, P<0.01, Fig. 5i). In sum, these results show that initially BCCs possess 
mesenchymal characteristics that may favour the TEM across the BBB and, once inside 
the brain, tumour cells undergo a total or partial MET to acquire the epithelial phenotype 
necessary to form metastases.  
 
3.3. Metastasization involves a disruption of the BBB by the paracellular 
pathway 
It has been referred that there is an increase of vascularization during the formation 
of brain metastasis, which is associated to a disruption of intercellular junctions of ECs 
that compose the blood vessel walls and, in turn, to an increase of BBB permeability (Fan 
et al. 2011, Avraham et al. 2014). In addition, the TEM of BCCs across the brain 
endothelium was only described as occurring via paracellular migration (Fan and Fu 
2016), a pathway that involved the interaction between the malignant cell and the 
endothelial junctions. Thus, we investigated the temporal evolution of the BBB 
permeability based on analysis of the TJ protein claudin-5 immunoreactivity (Fig. 6) and 
the entrance into the parenchyma of the blood-borne component thrombin (Fig. 7) in the 
cerebellum, cranial hippocampus, and striatum of control and 4T1 injected mice. 
Regarding claudin-5, we observed that this TJ protein is expressed at blood vessels (Fig. 
6a, b, and c). At early stages of the process of brain metastasization, claudin-5 had a 
normal distribution forming a continuous or a punctate line at the junction of cell-cell 
contact, however at 7 days this TJ protein showed an irregular and discontinuous 
distribution. Curiously, the observation of claudin-5 labelling at 10 days suggested a 
normal distribution of this TJ protein, similarly to that observed at early stages. Analysis 
of claudin-5 immunoreactivity of ECs of control and 4T1 injected mice showed a decrease 
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Fig. 6 Endothelial tight junction protein claudin-5 changes along the process of brain 
metastasization of breast cancer. Cerebellum, cranial hippocampus, and striatum sections 
of control mice and of mice at different times post-tumour cell inoculation were processed 
for immunofluorescence analysis of claudin-5 immunoreactivity. Representative 
immunohistological patterns of the claudin-5 in cerebellum (a), cranial hippocampus (b), 
and striatum (c). Semi-quantitative analysis of the claudin-5 immunoreactivity in 
endothelial cells junctions per field in cerebellum (d), cranial hippocampus (e), and 
striatum (f). *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, ##P<0.01 between 
indicated groups. 
Capturing changes in the blood-brain barrier and brain parenchyma during  
brain metastasization of breast cancer 
78 
 
over time, and that this decrease was significant at 7 days in both cranial hippocampus 
(42% vs. control, P<0.001, Fig. 6e) and striatum (34% vs. control, P<0.01, Fig. 6f). At 
this timepoint, the cerebellum also showed a 33% decrease of claudin-5 immunoreactivity 
as compared with the control (Fig. 6d), even though not significant. Remarkably, a 27% 
increase of claudin-5 immunoreactivity between 7 and 10 days was observed in cranial 
hippocampus (P<0.05, Fig. 6e), but not reaching the control values. Although not 
significant for the other brain regions, this increase was also observed in cerebellum (8%, 
from 7 to 10 days) and in striatum (19%, from 7 to 10 days). Thus, these results show that 
the migration of BCCs into the brain is accompanied by a disruption of intercellular 
junctions of the ECs that compose the BBB, suggesting an hyperpermeability by the 
paracellular route that may be associated with the migration of malignant cells across 
BBB endothelium. Moreover, these results also suggest that the BBB has the ability to 
repair, at least partially, its barrier properties after the passage of metastatic tumour cells 
into the brain.  
In addition to claudin-5 immunoreactivity, we investigated if the disruption of 
endothelial junctions is accompanied by the entrance into the brain parenchyma of 
thrombin, used as an indicator of BBB disruption (Janota et al. 2015). To this end, we 
measured the total number of thrombin deposits per section (Fig. 7), which were normally 
localized near blood vessels and occasionally near metastasis. Small thrombin deposits 
were already evident at 3 days post-tumour cell injection (P<0.05 in striatum, Fig. 7f), in 
line (Fig. 7a, b, and c). An increase of the dimensions of thrombin deposits was observed 
in all three brain regions of 4T1 injected mice from 3 to 7 days, further increasing until 
10 days. Similarly to deposits dimensions, an increase of the number of thrombin deposits 
was also detected in all three brain regions along the process of brain metastasization (Fig. 
7d, e, and f). Interestingly, the higher number of thrombin deposits was detected in the 
cranial hippocampus (Fig. 7e), which was the region presenting the lower claudin-5 
immunoreactivity of ECs between 5 hours and 7 days, which suggests a higher 
permeability of the BBB (Fig. 6e). Remarkably, the highest number of thrombin deposits 
at 10 days did not correspond to the lower claudin-5 immunoreactivity at 7 days. Thus, 
the results of claudin-5 immunoreactivity taken together with the results of thrombin 
suggest an increase of BBB permeability along the brain metastasization process. 
Moreover, they suggest that there is some recover of the TJ protein claudin-5 integrity, 
which is not enough to prevent the entrance of the blood-borne component thrombin at 
later stages.  
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Fig. 7 Entrance of the blood-borne component thrombin into the brain parenchyma along 
the process of brain metastasization of breast cancer. Cerebellum, cranial hippocampus, 
and striatum sections of control mice and of mice at different times post-tumour cell 
inoculation were processed for immunofluorescence analysis of the blood-borne 
component thrombin. Representative immunohistological patterns of thrombin in 
cerebellum (a), cranial hippocampus (b), and striatum (c), where the arrowheads point to 
thrombin deposits. Semi-quantitative analysis of total number of thrombin deposits per 
section in cerebellum (d), cranial hippocampus (e), and striatum (f). *P<0.05, ***P<0.001 
vs. control; #P<0.05, ###P<0.001 between indicated groups. 
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Fig. 8 Microvascular density changes along the process of brain metastasization of breast 
cancer. Cerebellum, cranial hippocampus, and striatum sections of control mice and of 
mice at different times post-tumour cell inoculation were processed for 
immunofluorescence analysis of endothelial protein of tight junctions claudin-5. 
Representative immunohistological patterns of claudin-5 in cerebellum (a), cranial 
hippocampus (b), and striatum (c). Semi-quantitative analysis of the area of blood vessels 
per brain area in cerebellum (d), cranial hippocampus (e), and striatum (f). *P<0.05 vs. 
control. 
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3.4. Formation of brain metastasis requires increased vascularization 
Previous studies have associated the formation of primary and secondary tumours 
to an increased vascularization (Monsky et al. 2002, Tang et al. 2005, Avraham et al. 
2014), which prompted us to investigate the temporal evolution of microvascular density 
in the present study. Cluster of differentiation (CD)31, CD34, and tomato lectin are three 
widely used endothelial markers of microvessels (Bell et al. 2010). However, we did not 
obtain any specific labelling in our tissue sections for CD31 and CD34, whereas tomato 
lectin also labels epithelial cells and, thus, malignant cells with an epithelial phenotype, 
as shown in Figure 3. As an alternative, we analysed claudin-5-labeled sections to 
determine the density occupied by the microvasculature in the cerebellum, cranial 
hippocampus, and striatum of control and 4T1 injected mice (Fig. 8). Observation of 
claudin-5 stained sections of control mice suggested that the cerebellum and the striatum 
were more vascularized than the cranial hippocampus (Fig. 8a, b, and c). The 
vascularization augmented in all three brain regions along time in 4T1 injected mice. 
However, this increase was accompanied by a slight decrease of microvascular density 
from 7 to 10 days. The microvessel density determined in control mice was 0.014 
μm2/μm2 in striatum (Fig. 8f), 0.013 μm2/μm2 in the cerebellum (Fig. 8d), and 0.010 
μm2/μm2 in cranial hippocampus (P<0.05 vs. striatum; Fig. 8e). Regarding 4T1 injected 
mice, it was not observed a significant increase of microvessel density in cerebellum and 
striatum along time compared to control mice, while in cranial hippocampus a significant 
increase of ~2-fold between the control and 7 days post-tumour cell inoculation was 
observed (P<0.05, Fig. 8e). Thus, the process of brain colonization by BCCs appears to 
be associated with hypervascularization in cranial hippocampus. 
 
3.5. Malignant cells express PDGF-B 
We wanted to know if BCCs colonizing the brain express the growth factor 
PDGF-B that was shown to be expressed by malignant cells associated to lymphatic and 
bone metastasization (Lev et al. 2005, Schito et al. 2012). For that purpose, we analysed 
PDGF-B-positive cells along time (Fig. 9). Curiously, in all three brain regions, this 
ligand was predominantly expressed by tumour cells normally located near a blood 
vessel, rather than by ECs (Fig. 9a, b, and c). Analysis of PDGF-B-positive cells in 
cerebellum (Fig. 9d), cranial hippocampus (Fig. 9e), and striatum (Fig. 9f) showed that 
the number of cells expressing this ligand was low at 5 hours, not showing a significant 
alteration of the number of positive cells compared to control. PDGF-B-positive cells  
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Fig. 9 Changes in the expression of the platelet-derived growth factor B (PDGF-B) by 
breast cancer cells along the process of brain metastasization. Cerebellum, cranial 
hippocampus, and striatum sections of control mice and of mice at different times post-
tumour cell inoculation were processed for immunohistochemical analysis of PDGF-B. 
Representative immunohistological patterns of PDGF-B in cerebellum (a), cranial 
hippocampus (b), and striatum (c), where the arrowheads point to the individual cells that 
express this growth factor. Semi-quantitative analysis of PDGF-B-positive cells per field 
in cerebellum (d), cranial hippocampus (e), and striatum (f). **P<0.01 vs. control. 
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were already evident at 3 days, reaching a fold around 100 or higher of positive cells at 
10 days post-tumour cell inoculation in all brain regions. Thus, these results show that the 
expression of PDGF-B by tumour cells increases from the timepoint where entry of these 
cells into the brain occurs to the formation of well-established brain metastasis.  
 
3.6. Malignant cells express CXCR4 
Previous work suggested that the arrival of viable cancer cells to the brain can 
result from a trapping of circulating tumour cells (CTCs) in small vessels of this 
secondary organ driven by organ-derived chemoattractants, being one of the most studied 
pairs the CXCR4 and its ligand CXCL12 (Hujanen and Terranova 1985, Salmaggi et al. 
2014). Thus, it seems that there is an important link between CXCR4/CXCL12 axis and 
the homing of carcinoma cells into the brain, contributing to metastatic progression. In 
order to understand the temporal evolution of entrance of CXCR4-positive tumour cells 
into the brain along the metastasization of this secondary organ, we measured the number 
of cells expressing the receptor per field (Fig. 10). Interestingly, CXCR4-positive cells 
were only observed as individual cells and not in well-established metastases (Fig. 10a, 
b, and c). Analysis of 4T1 injected mice showed that the number of CXCR4-positive cells 
was higher at 3 days than any other timepoint (Fig. 10d, e, and f). This result is in line 
with the analysis of vimentin-positive cells at 5 hours and 3 days (Fig. 3), since either for 
CXCR4 or for vimentin, an increase of malignant cells extravasating at these two 
timepoints was already observed. In addition, it was interesting to observe a slight 
decrease of CXCR4-positive cells at 7 and 10 days compared to 3 days, suggesting a 
continuous entrance of malignant cells along the process of brain metastasization. 
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Fig. 10 Changes in the expression of cysteine-X amino acid-cysteine receptor 4 (CXCR4) 
by breast cancer cells along the process of brain metastasization. Cerebellum, cranial 
hippocampus, and striatum sections of control mice and of mice at different times post-
tumour cell inoculation were processed for immunofluorescence analysis of CXCR4. 
Representative immunohistological patterns of CXCR4 in cerebellum (a), cranial 
hippocampus (b), and striatum (c), where the arrowheads point to individual cells that 
express this receptor. Semi-quantitative analysis of the number of CXCR4-positive cells 
per field in cerebellum (d), cranial hippocampus (e), and striatum (f). *P<0.05, **P<0.01 
vs. control. 
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4. Discussion 
Compared to other ‘target organs’ of BCCs, such as the bone, the mechanisms 
responsible for brain metastasis formation remain poorly understood and substantially 
less investigated. The brain is a very peculiar organ protected by the BBB, which 
represents the tightest endothelial barrier in the organism (Cardoso et al. 2010). However, 
this barrier allows the transmigration of malignant cells into the brain (Molnár et al. 
2016), and consequent formation of metastases in this secondary organ. It is nowadays 
believed that the interaction between the metastatic cells and BMVECs plays an important 
role in brain metastasization of BC, namely, in promoting the attraction of cancer cells 
into the brain vasculature, their transmigration, and even tumour-associated vascular 
development (Müller et al. 2001, Zhao et al. 2011, Fan and Fu 2016). Prior to TEM across 
the BBB into the brain parenchyma, CTCs adhere to the brain endothelium (Kienast et al. 
2010, Stoletov et al. 2010). However, the features of malignant cells present during the 
TEM and along the colonization of this secondary organ are still unclear. In addition, 
BBB integrity is intimately associated with the route used by malignant cells to transpose 
the brain endothelium, and its role in the process of brain metastasization is largely 
unexplored. The only route described in the brain is the paracellular pathway, in which 
malignant cells must interact with the intercellular junctions of two BMVECs to enter the 
brain (Fan and Fu 2016, Vandenhaute et al. 2016). Nonetheless, it is unkown whether the 
passage of tumour cells keeps the BBB intact or whether BBB has the ability to repair its 
barrier properties after the passage of metastatic cancer cells into the brain. Thus, we 
aimed to understand and characterize the process of brain metastases formation, by 
examining the temporal profile of BCCs metastasization to the brain, metastasizing cells 
phenotype, BBB integrity, vascular density, and signalling molecules involved in 
attraction and proliferation of malignant cells during disease progression. 
To induce the formation of brain metastases of BC, we used the 4T1 cells, which 
is one of the most aggressive metastatic murine BCC lines able to colonize the brain (Tao 
et al. 2008, Gao et al. 2011). The inoculation of tumour cells into the right common 
carotid artery not only reflects the haematogenous dissemination (Saito et al. 2008), one 
route used by cancer cells to escape from the primary tumour, but also directs the 
malignant cells to the brain, allowing the formation of metastases solely in this secondary 
organ (Zhang et al. 2008, Lorger and Felding-Habermann 2010). As brain metastasization 
progressed, we observed metastasis within the parenchyma of cerebellum, cranial 
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hippocampus, and striatum that gradually occupy an increasing tumour area. Curiously, 
cerebella of 4T1 injected mice developed brain metastases with smaller dimensions 
compared to those formed in cranial hippocampi, and striata. This difference may be 
explained by the anatomical distance between the right common carotid artery and the 
cerebellum. Thus, the majority of malignant cells get trapped in brain regions closer to 
the inoculation site, such as cranial hippocampus and striatum, and the cells that do not 
get trapped take longer to reach the cerebellum and are a minority. Based on the temporal 
and special profile of establishment of brain metastasis, the majority of cancer cells arrest 
and extravasate into cranial hippocampus and striatum, and a minority into cerebellum. 
In addition, the number of 4T1 cells injected in mice is also a feature that allows the rapid 
intracranial growth of tumour cells, leading to death of some animals even after 10 to 14 
days post-tumour cell inoculation, as described previously (Lorger and Felding-
Habermann 2010).  
We analysed the time-course of cancer cell extravasation into the brain 
parenchyma and characterized the phenotype expressed by the malignant cells during the 
exit from bloodstream and along the brain metastatic process. A previous in vivo study, 
using the same method of cancer cell inoculation and bioluminescence imaging, showed 
that 4T1 cells were readily detected throughout the brain parenchyma in very early stages 
of brain metastasization process, being detected inside the brain even 1 day post-tumour 
cell inoculation (Lorger and Felding-Habermann 2010). Furthermore, the extravasation 
process has been described as occurring after tumour cells arrest in small capillaries 
(Lorger and Felding-Habermann 2010, Stoletov et al. 2010). In line with these reports, 
here we show that BCCs are trapped in capillaries with a similar diameter to that presented 
by the carcinoma cells even 5 hours post-tumour cell injection. These cells present 
mesenchymal characteristics expressing both N-cadherin and vimentin proteins, whereby 
the fusiform morphology favours the penetration of brain endothelium by cancer cells. 
The upregulation of these mesenchymal markers expression is associated to tumour 
progression and increase of cancer cell invasiveness (Agiostratidou et al. 2007, Calaf et 
al. 2014). N-cadherin is a transmembrane adhesion molecule normally found in neural, 
mesenchymal and connective cells and is expressed by both BCCs and BMVECs 
(Harzheim et al. 2004, Strell and Entschladen 2008), allowing the attachment of the 
malignant cells to the endothelial ones. Furthermore, we found that once in well-
established metastasis, malignant cells do not express N-cadherin, suggesting that these 
cells downregulate the expression of this adhesion molecule, and probably up-regulate 
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the expression of other molecules, such as endothelial-cadherin, responsible for 
interactions between epithelial cells, as previous described (Chao et al. 2012). On the 
other hand, vimentin is an intermediate filament protein involved in cytoskeleton 
rearrangement, which in turn contributes to cell motility. Moreover, vimentin is involved 
in the regulation of the expression of Slug, an EMT-related transcription factor, which 
enhances cancer malignancy (Herrmann et al. 1996, Qiao et al. 2015). In addition to 
vimentin-positive cells localized inside or near blood vessels, malignant cells in well-
established metastases also express this mesenchymal marker. Thus, this result suggests 
that the BCCs undergo a partial MET. 
Based on previous observations of MET in brain metastasis developed by BCCs 
(Chao et al. 2012, Yoshida et al. 2014), we expanded our analysis to include other 
epithelial marker, pan Cytokeratin, to discern whether a full or partial MET occurs. At 
early timepoints, the majority of the cancer cells express mainly vimentin. This result 
showed that initially BCCs possess mesenchymal characteristics that may favour the 
TEM across the BBB. Over time, it is not surprising to observe an increase of pan 
Cytokeratin expression in tumour cells, revealing that once inside the brain malignant 
cells acquire the epithelial characteristics to favour the formation of well-established 
metastases. Curiously, at later stages of the brain colonization, the majority of BCCs 
express both mesenchymal and epithelial markers, suggesting that the malignant cells 
maintain their phenotypic plasticity by undergoing a partial MET, as previously described 
using BC samples from patients with brain metastases (Chao et al. 2012). These cells, as 
the ones that only express vimentin, have the ability to migrate to other areas of the brain, 
where they can establish new secondary tumours. The mesenchymal phenotype expressed 
by BCCs was also suggested as being a tumour protective mechanism against 
inflammatory or chemotherapeutic insult (Chao et al. 2012). It is also noteworthy to 
mention the observation of metastases growing around or near blood vessels. Once BBB 
is crossed, carcinoma cells are able to spread along brain capillaries, initiating brain 
metastatic lesion formation in association with vasculature (Carbonell et al. 2009, 
Stoletov et al. 2013, Valiente et al. 2014). This location of cancer cells favours the 
proliferation not only because the cells have an optimal oxygen supply and access to 
nutrients, but also because the BBB provides protection against antitumour immunity and 
chemotherapeutics drugs (Carbonell et al. 2009, Alkins et al. 2013, Yoshida et al. 2014). 
The BBB impermeability is most pronounced for molecules greater than 800 Da 
and the TJ proteins, such as claudin-5, play a crucial role in regulating endothelial 
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permeability (Nitta et al. 2003, Ohtsuki et al. 2007). However, one of the key features of 
brain metastasization is the paracellular TEM of BCCs across the BBB. This 
transmigration route involves the BBB breakdown via disruption of endothelial junctions, 
which in turn causes an increase of BBB permeability (Lee et al. 2003, Avraham et al. 
2014, Rodriguez et al. 2014). Our results corroborate these studies by showing a decrease 
of claudin-5 immunoreactivity and an increase of thrombin deposits in brain parenchyma. 
Of note in our study, the detection of the higher number of blood-borne component 
deposits in the parenchyma does not happen at the same timepoint of the lower value of 
claudin-5 immunoreactivity. This could be due to the continuous entrance of thrombin 
once the cancer cell causes an impairment in BBB enough for a 37 kDa molecule to be 
able to cross the brain endothelium. The continuous thrombin passage is confirmed by 
the number of thrombin deposits that progressively augment in brain parenchyma. The 
increase of this protein is an early event in mice injected with 4T1, suggesting that BBB 
disruption occurs as a result of the early passage of BCCs across the brain endothelium. 
Thence, the entire extravasation process of a 4T1 cancer cell must occur in less than 3 
days since at this timepoint thrombin is already detected in brain parenchyma. Thus, 
contrarily to the duration of TEM estimated in vivo (3 to 5 days) (Lorger and Felding-
Habermann 2010), this result demonstrated that extravasation of triple-negative cells, 
such as 4T1 cancer cells, occurs in shorter period than the estimated one. In addition, the 
proliferation of cancer cells and formation of macrometastases around blood vessels can 
be other explanation for the BBB impairment. Interestingly, at the last timepoint of our 
study, there is an increase of claudin-5 immunoreactivity, suggesting that the BBB 
possesses a repair and/or reorganizing capacity that allows the reestablishment of 
endothelial junctions.  
We analysed how brain microvasculature density through measurement of the area 
of blood vessels visualized by claudin-5 labelling, since previous studies described an 
increased vascularization during the formation of secondary tumours (Monsky et al. 2002, 
Avraham et al. 2014). Herein, we further show that the hypervascularization occurs only 
in cranial hippocampus. This hypervascularization at a later stage may be related to the 
fact that initially cancer cells obtain an adequate blood supply by vascular co-option 
(Leenders et al. 2002, Bugyik et al. 2011), not requiring the formation of new blood 
vessels. Vascular co-option and angiogenesis have distinct contributions during the 
initiation of micrometastases, depending not only on the cell numbers in the microtumour, 
but also on blood supply of local microenvironment (Zhao et al. 2011). In addition, we 
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hypothesize that the heterogeneity of brain microvasculature might also explain the 
hypervascularization only observed in cranial hippocampus. Although a characterization 
of the differences regarding brain microvasculature within the different brain regions 
under physiological conditions has not been performed, our results of control mice 
suggest that the cranial hippocampus has lower microvessel density compared to striatum. 
Thus, the lower microvessel density and the higher tumour area in cranial hippocampus 
may favour the formation of new vessels, leading to hypervascularization in this brain 
region.  
To the best of our knowledge, this study is the first one to provide quantitative 
data of the temporal and spatial expression of PDGF-B by BCCs during the formation of 
brain metastases. PDGF-B is a growth factor involved in regulation of cellular processes 
such as migration, proliferation, and differentiation (Lindberg and Holland 2012). 
Regarding BC, both benign and malignant breast cells have been described as expressing 
PDGF-B in lymphatic and bone metastases (Coltrera et al. 1995, Lev et al. 2005, Schito 
et al. 2012). In addition, the expression of this growth factor in tumour cells can be 
directly induced by the transcription factor LIM homeobox gene 2 (Lhx2), which is 
upregulated during EMT in BCCs (Kuzmanov et al. 2014). The Lhx2 has a dual role 
during EMT and tumour progression: by inducing the expression of PDGF-B, Lhx2 
promotes an autocrine PDGF-B/PDGF receptor beta (PDGFR-β) loop required for cell 
migration, invasion and metastatic dissemination and paracrine PDGF-B/PDGFR-β 
signalling to support blood vessel functionality and, thus, tumour growth (Kuzmanov et 
al. 2014). Regarding the nervous tissue, PDGF signalling has been only associated to 
glioma cells that are dependent of this growth factor to maintain proliferative capacity 
(Uhrbom et al. 2004). In addition, a recent study demonstrated that highly invasive glioma 
initiating cells express high levels of PDGF-B, and the PDGF signalling may have a role 
in the transformation of host glial cells that have a high expression of PDGF receptors 
(Chen et al. 2015). Similarly to glioma cells, our results show that BCCs also express the 
growth factor PDGF-B that may favour their own proliferation and subsequent formation 
of brain metastases. Thus, these data point to PDGF-B as a player in the development of 
brain metastases by BCCs and a new therapeutic target for future treatment. 
Lastly, we studied the temporal evolution of CXCR4 expression by cancer cells 
in brain parenchyma. Our results reveal that extravasating BCCs express the receptor 
CXCR4, which is in line with the association of CXCR4 to an increased migratory and 
invasive potential required during the haematogenous journey to the brain and during the 
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penetration across the brain endothelium (Cronin et al. 2010). The observation of 
CXCR4-positive cells in brain parenchyma along the metastatic process suggests a 
continuous entrance of these cells even 10 days post-tumour cell injection. Interestingly, 
brain metastases formed by 4T1 cells do not express CXCR4. This result suggests that 
the downregulation of CXCR4 expression is associated to decrease migratory and 
invasive capacity of the malignant cells. However, not only the expression of vimentin 
contradicts the loss of this capacity, but also CXCR4 expression is upregulated by 
hypoxia, which has been associated with brain metastases of BC (Cronin et al. 2010, Saha 
et al. 2011). 
In conclusion, our findings suggest that cancer cells induce a variety of BBB and 
brain parenchyma alterations, as schematically depicted in Figure 11, that can be target 
in order to prevent the brain metastasis by BCCs. Therefore, BBB stabilizing drugs or 
drugs that contribute to vascular density maintenance may have beneficial effects in 
metastasization of BC by preventing the entrance and dissemination of tumour cells into 
the brain. In addition, our results suggest that PDGF-B plays an important role in cancer 
cell proliferation and targeting this growth factor or its receptors may be useful in 
treatment of secondary tumours. Thus, this study provides new insights into the 
mechanisms of brain metastatic cancer. 
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Concluding remarks and perspectives 
Metastasis of breast cancer (BC) to the central nervous system (CNS) continues 
to be a great challenge. Despite the considerable improvement made in BC treatment over 
the past decades, the brain metastasization remains an unsolved problem. Thus, it is 
important to prevent the entrance of malignant cells into the brain and the establishment 
of metastasis in this secondary organ. The CNS is protected against neurotoxicity and 
entry of pathogens and cells by the blood-brain barrier (BBB), a highly selective barrier 
that prevents the delivery of the current chemotherapeutic agents, but is not able to block 
the entrance of cancer cells into the brain. In fact, the BBB has a pivotal role along the 
process of brain metastasization, namely during the transendothelial migration (TEM) via 
paracellular route, making the BBB modulation as a therapeutic target in metastatic BC. 
Hence, there could be two approaches according to the stage of BC: for early stages or 
metastatic spread to organs such as the bones, lungs or liver, the sealing of BBB must 
prevent the entrance of malignant cells, and for metastatic stages when the brain 
metastases are already formed, the improvement of BBB permeability would allow the 
entrance of chemotherapeutic agents. It is also important to understand the mechanisms 
that lead to BBB disruption and whether this disruption is a reversible event. Notably, TJs 
have a crucial role in BBB integrity, and their modulation may be a promising approach 
to prevent the extravasation of tumour cells into CNS. In addition, there are evidences 
that the neurovascular unit cells are involved in TJ formation and modulation, being also 
important to study the interactions between these cells and the mentioned junctions. 
Further research in this field may reveal more therapeutic opportunities to prevent brain 
metastasis formation associated with BBB breakdown.  
Although there is only evidence that malignant cells use the paracellular route to 
migrate into the brain, the hypothesis that cancer cells may also migrate through the 
endothelial barrier by transcellular TEM remain to be established. Thus, it could be 
interesting to find out if the malignant cells also cross the brain endothelium via 
transcellular route. Since the myosin light chain kinase (MLCK) activation and 
contraction of cytoskeletal myosin in endothelial cells (ECs) have been described to be 
involved in transcellular pathway during intravasation into blood vessels, the study of 
these proteins could be a starting point. Then, the study could evolve to the establishment 
of the expression of proteins involved in vesicular transport, such as caveolin-1, and the 
determination of basement membrane and extracellular matrix proteins expression. Thus, 
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this study could provide clues about the transcellular migration of BC cells (BCCs) across 
the brain endothelium. 
In the work here presented, it was shown that the formation of brain metastases 
could occur through the continuous entrance of malignant cells into the brain and involve 
the expression of growth factors that favour the tumour cell proliferation. Firstly, to 
complete the present study and confirm whether the platelet-derived growth factor B 
(PDGF-B)-positive cells are proliferating, it would be interesting to perform a double 
labelling with PDGF-B and Ki-67, a proliferation marker. Secondly, the downregulation 
of PDGF-B expression in BCCs could be a promising therapeutic target. Thirdly, since 
the PDGF-B/platelet-derived growth factor receptor beta (PDGFR-β) signalling is 
involved in the cross-talk between ECs and pericytes and these latter cells are the 
neurovascular unit cells less studied in brain metastasization, it would be interesting to 
assess whether the pericytes change their localization in blood vessel wall to allow the 
passage of malignant cells or the passage of malignant cells induces the reduction the 
number of pericytes around the blood vessels. 
Despite the progress in the current knowledge about the mechanisms behind the 
process of brain metastasization, there are still major gaps in our understanding that must 
be filled. So, a better comprehension of the time-course and cellular and molecular players 
that are involved in the process of brain metastasization of BC may have a huge impact 
for the identification of novel targets against the formation of secondary tumours. 
Hopefully, clarification of these issues will allow to timely establish preventive 
approaches to avoid the occurrence of brain metastasis and delay the cancer progression. 
 
 
